Development and Characterisation of Simvastatin Loaded Chitosan Nanoparticles for Sustained Drug Delivery by Rajakumari, R
 DEVELOPMENT AND CHARACTERIZATION OF SIMVASTATIN LOADED 
CHITOSAN NANOPARTICLES FOR SUSTAINED DRUG DELIVERY 
 
A Dissertation submitted to 
THE TAMILNADU DR.M.G.R.MEDICAL UNIVERSITY 
CHENNAI - 600 032. 
 
In partial fulfillment of the requirements for the award of the degree of 
Submitted by 
Reg. No. 261211257 
Under the Guidance of 
Mr. K. Elango, M.Pharm., (Ph.D.) 
Professor and Head 
Department of Pharmaceutics 
 
COLLEGE OF PHARMACY 
MADRAS MEDICAL COLLEGE 
CHENNAI – 600 003 
 
APRIL 2014 
  
  
  
                                                                                                      
DEPARTMENT OF PHARMACEUTICS 
COLLEGE OF PHARMACY 
MADRAS MEDICAL COLLEGE 
CHENNAI – 600 003 
TAMIL NADU 
 
DATE: 
 
 
 
 
This is  to  certify  that  the  Dissertation  entitled “DEVELOPMENT AND 
CHARACTERISATION OF SIMVASTATIN LOADED CHITOSAN 
NANOPARTICLES FOR SUSTAINED DRUG DELIVERY” submitted  by  the  
candidate with Register  No. 261211257 for  The  Tamil  Nadu  Dr.  M.G.R. Medical 
University examinations is evaluated. 
 
 
 
 
       Evaluated. 
 
  
  
  
                                                                                                      
 
 
 
 
 
 
 
COLLEGE OF PHARMACY 
MADRAS MEDICAL COLLEGE 
CHENNAI – 600 003 
TAMIL NADU 
 
 
CERTIFICATE 
This is to certify that the Dissertation entitled “DEVELOPMENT AND 
CHARACTERISATION OF SIMVASTATIN LOADED CHITOSAN 
NANOPARTICLES FOR SUSTAINED DRUG DELIVERY” submitted by the 
candidate with Reg. No. 261211257 in partial fulfillment of the requirements for the 
award of the degree of MASTER OF PHARMACY in PHARMACEUTICS by The 
Tamil Nadu Dr. M.G.R. Medical University is a bonafide work done by him during the 
academic year 2013-2014. 
 
 
 
Place: Chennai-03. 
Date:                  (Dr. A.Jerad Suresh) 
 
 
  
  
  
                                                                                                      
DEPARTMENT OF PHARMACEUTICS 
COLLEGE OF PHARMACY 
MADRAS MEDICAL COLLEGE 
CHENNAI – 600 003 
TAMIL NADU 
 
CERTIFICATE 
 
 
 
 
This is to certify that the Dissertation entitled “DEVELOPMENT AND 
CHARACTERISATION OF SIMVASTATIN LOADED CHITOSAN 
NANOPARTICLES FOR SUSTAINED DRUG DELIVERY” submitted by the 
candidate with Reg. No. 261211257 in partial fulfillment of the requirements for the  
award of the degree of MASTER  OF  PHARMACY in PHARMACEUTICS by The 
Tamil Nadu Dr. M.G.R. Medical University is a bonafide work done by him during the 
academic year 2013-2014. 
 
 
 
Place: Chennai-03. 
Date:                  (Prof. K.Elango) 
 
 

  
 
ACKNOWLEDGEMENT 
 
“Gratitude makes sense of our past, brings peace for today and creates a 
vision for tomorrow”  
 
I  consider  this  as  an  opportunity  to  express  my  gratitude  to  all  the 
dignitaries  who  have  been  involved  directly  or  indirectly  with  the  successful 
completion of this dissertation. The satisfaction that accompanies the successful 
completion of any task would  be  incomplete  without  mention  of  the  people  who  
made  it  possible  with constant guidance, support and encouragement that crows all 
effort with success.  
Many Thanks to ALMIGHTY GOD, for it, He who began this work in me 
and carried it to completion.  It  is He  who  has blesses  me  with  the  people  
whose names I feel privileged to mention here. 
    I acknowledge my sincere thanks to Prof. Dr.  A.  Jerad Suresh 
M.Pharm., Ph.D., MBA, Principal, College of Pharmacy, Madras Medical College, 
Chennai, for his continuous support in carrying out my project work in this 
institution. 
  It  is  with  great  pleasure  that  I  place  on  record a  deep  sense  of  
gratitude  and Heartfelt thanks to my guide Mr.K.Elango, M.Pharm.,(Ph.D.), 
Head,  Department  of  Pharmaceutics,  College  of Pharmacy, Madras Medical 
College, Chennai, for their help, support and constant encouragement throughout the 
progress of this work.  It was really a great experience working under them and their 
guidance, which was of immense help in my project work without which it would 
have been an unachievable task. 
 It’s a great pleasure for me to acknowledge my sincere thanks to all my 
teaching staff members Dr. N.Deattu, M.Pharm., Ph.D, Mrs. S.Daisy 
Chellakumari, M.Pharm., Mrs.  R.Devi Damayanthi, M.Pharm., of the  
Department  of  Pharmaceutics, College  of Pharmacy, Madras Medical College, 
Chennai-03.  
 
  
I  extent  my  thanks  to  all  non-teaching  staff  members 
Mr.R.Marthandam and  Mrs.R.Shankari  Department  of Pharmaceutics, College 
of Pharmacy, Madras Medical College, Chennai-03. 
The words are insufficient to thank my mentors Vengatesh.S, Pasupathi 
Raja. M and Sivasubramani.R.V and who stood beside me each and every step 
during my project and given me constant support. 
I have no words to express my pleasure in thanking my dear friends David 
selva Kumar.D, Chinnaraja.S, Ramu.P, Kishore kumar.S, Catherin.U, Priya.B, 
Akilandeshwari.A, Suhasini.G and all others who are behind me supporting my 
endeavour.  
I extend my cordial thanks to my seniors and to my juniors for their kind 
support and co-operation.  
Most of all I would like to thank my beloved parents, brother, and my dearest 
friends for  their  priceless  support,  love  and  encouragement  throughout  the  
entire  tenure  of  this course. 
 
  
 
 
 
 
  
 
Contents 
S.No. Contents Page No. 
01 Introduction 1 
02 Literature review 23 
03 Aim and plan of work 35 
04 Rationale of the study 37 
05 Disease profile 38 
06 Drug profile 48 
07 Excipients profile 51 
08 Materials and methods 56 
09 Formulation development 58 
10 Results and discussion 71 
11 Summary and conclusion 100 
12 References 102 
List of Abbreviations 
AI   Atherogenic Index 
CS   Chitosan 
CMC   Carboxy Methyl Cellulose 
DSC   Differential Scanning Calorimetry 
FTIR   Fourier Transform Infra-Red Spectroscopy 
LB   Libermann- Burchard 
LDL   Low Density Lipoproteins 
PCS   Photon Correlation Spectroscopy 
PNPs   Polymeric Nanopaarticles 
PTA   Phospho Tungstic Acid 
TC   Total Cholesterol 
TG   Triglycerides 
SEM   Scanning Electron Microscopy 
VLDL   Very Low Density Lipoproteins 
XRD   X-Ray Differaction 
ml   millilitre 
µg   Microgram 
mg   milligram 
nm   nanometer 
 	
1. Introduction 
 
Department of Pharmaceutics, Madras Medical College Page 1 
 
1. INTRODUCTION 
1.1 DRUG DELIVERY SYSTEM
1
: 
Over the past three decades, a great deal of attention has been focused on the 
development of new drug delivery system. There are many reasons for the interest into this 
drug delivery system. They are 
 As bringing new drug entities into the market is an expensive and time 
consuming process, development of new drug delivery is profitable. 
 New system is needed to deliver novel, genetically engineered 
pharmaceuticals such as protein and peptides to their sites of action without 
biological inactivation. 
 To improve therapeutically efficacy and safety of conventional drug both by 
reducing size and number of doses. 
Two important features are important while developing a drug delivery system. i.e. It 
should deliver drug at a rate dictated by needs of body over the entire period of treatment and 
the drug should solely reach the site of action. 
1.2 NOVEL DRUG DELIVERY SYSTEM
 (2, 3)
 
The method by which a drug is delivered can have a significant effect on its efficacy. 
Some drugs have an optimum concentration range within which maximum benefit is derived, 
and concentrations above or below this range can be toxic or produce no therapeutic benefit 
at all. On the other hand, the very slow progress in the efficacy of the treatment of severe 
diseases, has suggested a growing need for a multidisciplinary approach to the delivery of 
therapeutics to targets in tissues. From this, new ideas on controlling the pharmacokinetics, 
pharmacodynamics, non-specific toxicity, immunogenicity, biorecognition, and efficacy of 
drugs were generated. These new strategies, often called drug delivery systems (DDS), are 
based on interdisciplinary approaches that combine polymer science, pharmaceutics, 
bioconjugate chemistry, and molecular biology. 
To minimize drug degradation and loss, to prevent harmful side-effects and to 
increase drug bioavailability and the fraction of the drug accumulated in the required zone, 
various drug delivery and drug targeting systems are currently under development. Among 
drug carriers one can name soluble polymers, microparticles made of insoluble or 
biodegradable natural and synthetic polymers, microcapsules, cells, cell ghosts, lipoproteins, 
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liposomes, and micelles. The carriers can be made slowly degradable, stimuli-reactive (e.g., 
pH or temperature-sensitive), and even targeted (e.g., by conjugating them with specific 
antibodies against certain characteristic components of the area of interest). Targeting is the 
ability to direct the drug-loaded system to the site of interest. Two major mechanisms can be 
distinguished for addressing the desired sites for drug release: (i) passive and (ii) active 
targeting. An example of passive targeting is the preferential accumulation of 
chemotherapeutic agents in solid tumors as a result of the enhanced vascular permeability of 
tumor tissues compared with healthy tissue. A strategy that could allow active targeting 
involves the surface functionalization of drug carriers with ligands that are selectively 
recognized by receptors on the surface of the cells of interest. Since ligand–receptor 
interactions can be highly selective, this could allow a more precise targeting of the site of 
interest. 
Controlled drug release and subsequent biodegradation are important for developing 
successful formulations. Potential release mechanisms involve: (i) desorption of surface-
bound /adsorbed drugs; (ii) diffusion through the carrier matrix; (iii) diffusion (in the case of 
nanocapsules) through the carrier wall; (iv) carrier matrix erosion; and (v) a combined 
erosion /diffusion process. The mode of delivery can be the difference between a drug’s 
success and failure, as the choice of a drug is often influenced by the way the medicine is 
administered. Sustained (or continuous) release of a drug involves polymers that release the 
drug at a controlled rate due to diffusion out of the polymer or by degradation of the polymer 
over time. Pulsatile release is often the preferred method of drug delivery, as it closely 
mimics the way by which the body naturally produces hormones such as insulin. It is 
achieved by using drug-carrying polymers that respond to specific stimuli (e.g., exposure to 
light, changes in pH or temperature). 
For over 20 years, researchers have appreciated the potential benefits of 
nanotechnology in providing vast improvements in drug delivery and drug targeting. 
Improving delivery techniques that minimize toxicity and improve efficacy offers great 
potential benefits to patients, and opens up new markets for pharmaceutical and drug delivery 
companies. Other approaches to drug delivery are focused on crossing particular physical 
barriers, such as the blood brain barrier, in order to better target the drug and improve its 
effectiveness; or on finding alternative and acceptable routes for the delivery of protein drugs 
other than via the gastro-intestinal tract, where degradation can occur. 
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Drug Delivery Carriers 
Colloidal drug carrier systems such as micellar solutions, vesicle and liquid crystal 
dispersions, as well as nanoparticle dispersions consisting of small particles of 10–400 nm 
diameter show great promise as drug delivery systems. When developing these formulations, 
the goal is to obtain systems with optimized drug loading and release properties, long shelf-
life and low toxicity. The incorporated drug participates in the microstructure of the system, 
and may even influence it due to molecular interactions, especially if the drug possesses 
amphiphilic and/or mesogenic properties. 
 
 
 
Fig.1: Schematic representation of various Pharmaceutical carriers 
 
 Nanotechnology
4
 
 
Nanotechnology is science of matter and material that deal with the particle size in 
nanometers. The word’ nano’ is derived from latin word, which means dwarf (1nm=10-9m). 
Nanomedicine deals with comprehensive monitoring, control, construction, repair, defense 
and improve human biological system at molecular level using engineered nanostructures and 
nanodevices. 
Pharmaceutical nanotechnology embraces applications of nanoscience to pharmacy as 
nanomaterials, and as devices like drug delivery, diagnostic, imaging and biosensor materials. 
Pharmaceutical nanotechnology has provided more fine-tuned diagnosis and focused 
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treatment of disease at a molecular level. It helps in detecting the antigen associated with 
diseases such as cancer, diabetes mellitus, neuro degenerative diseases, as well as detecting 
the microorganisms and virus associated with infections. In pharmacy size reduction has an 
important application as drugs in the nanometre size range enhance performance in a variety 
of dosage forms. 
ADVANTAGES OF NANOPARTICLES 
1. Increased surface area. 
2. Enhanced solubility. 
3. Increased rate of dissolution.  
4. Increased in oral bioavailability.  
5. Less amount of dose required & reduces the number of doses.  
6. Protection of drug from degradation.  
7. More rapid onset of therapeutic action.  
8. Achievement of drug targeting. 
9. Passive targeting of drugs to the macrophages present in the liver and Spleen. 
           10. Increased efficacy and therapeutic index. 
           11. Increased stability via encapsulation. 
           12. Improved pharmacokinetic effect. 
           13. Entrap both hydrophilic & lipophilic drug Protect entrapped drug from   
     enzymatic degradation. 
           14. Large variety of drugs (antineoplastic, antibiotic), peptides or protein (including  
     antibodies), viruses and bacteria can be incorporated into nanoparticles. 
           15. Nanoparticles encapsulated drugs are delivered intact to various tissue and cells  
     and can be released when nanoparticles are destroyed ,enabling site specific and  
     targeted drug delivery. 
            16. Other tissues and cells of the body are protected from drug until it is released by  
      nanoparticles thus decreasing drug toxicity. 
 
Polymers used in Nanoparticle 
 Polymeric Nanoparticles
5
 
The polymeric nanoparticles (PNPs) are prepared from biocompatible and 
biodegradable polymers in size between 10-1000 nm where the drug is dissolved, entrapped, 
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encapsulated or attached to a nanoparticle matrix. Depending upon the method of preparation 
nanoparticles, nanospheres or nanocapsules can be obtained. Nanocapsules are systems in 
which the drug is confined to a cavity surrounded by a unique polymer membrane, while 
nanospheres are matrix systems in which the drug is physically and uniformly dispersed
6,7
. 
The field of polymer nanoparticles (PNPs) is quickly expanding and playing an important 
role in a wide spectrum of areas ranging from electronics, photonics, conducting materials, 
sensors, medicine, biotechnology, pollution control and environmental technology
8-16
. PNPs 
are promising vehicles for drug delivery by easy manipulation to prepare carriers with the 
objective of delivering the drugs to specific target, such an advantage improves the drug 
safety
17
. Polymer-based nanoparticles effectively carry drugs, proteins, and DNA to target 
cells and organs. Their nanometre-size promotes effective permeation through cell 
membranes and stability in the blood stream. Polymers are very convenient materials for the 
manufacture of countless and varied molecular designs that can be integrated into unique 
nanoparticle constructs with many potential medical applications
18
. Several methods have 
been developed during the last two decades for preparation of PNPs, these techniques are 
classified according to whether the particle formation involves a polymerization reaction or 
nanoparticles form directly from a macromolecule or preformed polymer or ionic gelation 
method. 
 
Fig.2: Difference between the nanosphere and nanocapsule 
 
 Advantages of polymeric nanoparticles 
19, 20.
 
 Increases the stability of any volatile pharmaceutical agents, easily and cheaply 
fabricated in large quantities by a multitude of methods. 
 They offer a significant improvement over traditional oral and intravenous methods 
of administration in terms of efficiency and effectiveness.  
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 Delivers a higher concentration of pharmaceutical agent to a desired location.  
 The choice of polymer and the ability to modify drug release from polymeric 
nanoparticles have made them ideal candidates for cancer therapy, delivery of 
vaccines, contraceptives and delivery of targeted antibiotics. 
 Polymeric nanoparticles can be easily incorporated into other activities related to 
drug delivery, such as tissue engineering.  
 
Polymers used in preparation of nanoparticles  
Characteristic features of polymers
21.
 
A polymer used in controlled drug delivery formulations, must be: 
 Chemically inert 
 Non-toxic 
 Free of leachable impurities 
 An appropriate physical structure 
 With minimal undesired aging 
 Readily processable 
 
Classification:   
Polymers are classified as
22-25
 
 A) Natural polymers: 
 Gums (Ex. Acacia, Guar, etc.) 
 Chitosan 
 Gelatin 
 Sodium alginate 
 Albumin 
B) Synthetic polymers: 
      a) Nonbiodegradable:   
 Cellulosics 
 Poly(2-hydroxy ethyl methacrylate) 
 Poly (N-vinyl pyrrolidone) 
 Poly(methyl methacrylate) 
 Poly (vinyl alcohol). 
 Poly (acrylic acid). 
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 Polyacrylamide. 
 Poly (ethylene-co-vinyl acetate). 
 Poly (ethylene glycol). 
 Poly (methacrylic acid). 
    
      b) Biodegradable 
 Polylactides (PLA). 
 Polyglycolides (PGA). 
 Poly (lactide-co-glycolides) (PLGA). 
 Polyanhydrides. 
 Polyorthoesters. 
 Polycyanoacrylates 
 Polycaprolactone 
 
Originally, polylactides and polyglycolides were used as absorbable suture  material. 
The main advantage of these degradable polymers is that they are  broken down into 
biologically acceptable molecules that are metabolized and removed from the body via 
normal metabolic pathways. However, biodegradable materials do produce degradation by-
products that must be tolerated with little or no adverse reactions within the biological 
environment. 
 
Mechanism of drug release
21
 
 
The polymeric drug carriers deliver the drug at the tissue site by any one of the three 
general physicochemical mechanisms.  
1. By the swelling of the polymer nanoparticles by hydration followed by release 
through diffusion.  
2. By an enzymatic reaction resulting in rupture or cleavage or degradation of the 
polymer at site of delivery, there by releasing the drug from the entrapped inner core.  
3. Dissociation of the drug from the polymer and its de-adsorption/release from the 
swelled nanoparticles. 
 
Techniques of preparation  
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The properties of PNPs have to be optimized depending on the particular application. 
In order to achieve the properties of interest, the mode of preparation plays a vital role. Thus, 
it is highly advantageous to have preparation techniques at hand to obtain PNPs with the 
desired properties for a particular application. Different techniques like polymerization, 
preformed polymers or ionic gelation etc., are used. 
Methods for preparation of nanoparticles from dispersion of preformed polymer  
Dispersion of drug in preformed polymers is a common technique used to prepare 
biodegradable nanoparticles from poly (lactic acid) (PLA), poly (D, L-glycolide) (PLG), poly 
(D, L-lactide-co-glycolide) (PLGA) and poly (cyanoacrylate) (PCA). These can be 
accomplished by different methods described below.  
a) Solvent evaporation  
b) Nanoprecipitation  
c) Emulsification/solvent diffusion  
d) Salting out  
e) Dialysis  
f) Supercritical fluid technology (SCF) 
Methods for preparation of nanoparticles from polymerization of monomers  
a) Emulsion  
b) Mini emulsion  
c) Micro emulsion  
d) Interfacial polymerization  
e) Controlled/Living radical polymerization(C/LRP)  
Ionic gelation or coacervation of hydrophilic polymers 
Solvent evaporation  
Solvent evaporation was the first method developed to prepare PNPs. In this method, 
polymer solutions are prepared in volatile solvents and emulsions are formulated. In the past, 
dichloromethane and chloroform preformed polymer were widely used, but are now replaced 
with ethyl acetate which has a better toxicological profile. The emulsion is converted into a 
nanoparticle suspension on evaporation of the solvent for the polymer, which is allowed to 
diffuse through the continuous phase of the emulsion. In the conventional methods, two main 
strategies are being used for the formation of emulsions, the preparation of single-emulsions, 
e.g., oil-in-water (o/w) or double-emulsions, e.g., (water-in-oil)-in-water, (w/o)/w. These 
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methods utilize high-speed homogenization or ultrasonication, followed by evaporation of the 
solvent, either by continuous magnetic stirring at room temperature or under reduced 
pressure. Afterwards, the solidified nanoparticles can be collected by ultracentrifugation and 
washed with distilled water to remove additives such as surfactants. Finally, the product is 
lyophilized.
26, 27
 Particle size was found to be influenced by the type and concentrations of 
stabilizer, homogenizer speed and polymer concentration. In order to produce small particle 
size, often a high-speed homogenization or ultrasonication may be employed. 
 
Fig.3: Schematic representation of the solvent-evaporation technique
27
 
 
Nanoprecipitation  
Nanoprecipitation is also called solvent displacement method. It involves the 
precipitation of a preformed polymer from an organic solution and the diffusion of the 
organic solvent in the aqueous medium in the presence or absence of a surfactant
28-31
. The 
polymer generally PLA, is dissolved in a water-miscible solvent of intermediate polarity, 
leading to the precipitation of nanospheres. This phase is injected into a stirred aqueous 
solution containing a stabilizer as a surfactant. Polymer deposition on the interface between 
the water and the organic solvent, caused by fast diffusion of the solvent, leads to the 
instantaneous formation of a colloidal suspension. To facilitate the formation of colloidal 
polymer particles during the first step of the procedure, phase separation is performed with a 
totally miscible solvent that is also a non-solvent of the polymer. The solvent displacement 
technique allows the preparation of nanocapsules when a small volume of nontoxic oil is 
incorporated in the organic phase. Considering the oil-based central cavities of the 
nanocapsules, high loading efficiencies are generally reported for lipophilic drugs when 
nanocapsules are prepared. The usefulness of this simple technique
32
 is limited to water-
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miscible solvents, in which the diffusion rate is enough to produce spontaneous 
emulsification. Then, even though some water-miscible solvents produce a certain instability 
when mixed in water, spontaneous emulsification is not observed if the coalescence rate of 
the formed droplets is sufficiently high
33
. Although, acetone/dichloromethane (ICH, class 2) 
are used to dissolve and increase the entrapment of drugs, the dichloromethane increases the 
mean particle size
34
 and is considered toxic. This method is basically applicable to lipophilic 
drugs because of the miscibility of the solvent with the aqueous phase, and it is not an 
efficient means to encapsulate water-soluble drugs. This method has been applied to various 
polymeric materials such as PLGA, PLA, PCL, and poly (methyl vinyl ether-comaleic 
anhydride) (PVM/MA). This technique was well adapted for the incorporation of cyclosporin 
A, because entrapment efficiencies as high as 98% were obtained. Highly loaded 
nanoparticulate systems based on amphiphilic h-cyclodextrins to facilitate the parenteral 
administration of the poorly soluble antifungal drugs Bifonazole and Clotrimazole were 
prepared according to the solvent displacement method 
.  
Fig.4 Schematic representation of the nanoprecipitation technique. 
Surfactant is optional. 
 
Emulsification/solvent diffusion (ESD)  
This is a modified version of solvent evaporation method. The encapsulating polymer 
is dissolved in a partially water soluble solvent such as propylene carbonate and saturated 
with water to ensure the initial thermodynamic equilibrium of both liquids. In fact, to produce 
the precipitation of the polymer and the consequent formation of nanoparticles, it is necessary 
to promote the diffusion of the solvent of the dispersed phase by dilution with an excess of 
water when the organic solvent is partly miscible with water or with another organic solvent 
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in the opposite case. Subsequently, the polymer-water saturated solvent phase is emulsified in 
an aqueous solution containing stabilizer, leading to solvent diffusion to the external phase 
and the formation of nanospheres or nanocapsules, according to the oil-to-polymer ratio. 
Finally, the solvent is eliminated by evaporation or filtration, according to its boiling 
point.This technique presents several advantages, such as high encapsulation efficiencies 
(generally >70%), no need for homogenization, high batch-to-batch reproducibility, ease of 
scale-up, simplicity, and narrow size distribution. Disadvantages are the high volumes of 
water to be eliminated from the suspension and the leakage of water-soluble drug into the 
saturated-aqueous external phase during emulsification, reducing encapsulation efficiency
7,27
. 
As with some of the other techniques, this one is efficient in encapsulating lipophilic drugs
32
. 
Several drug-loaded nanoparticles were produced by the ESD technique, including 
mesotetra(hydroxyphenyl)porphyrin-loaded PLGA (p-THPP) nanoparticles, doxorubicin-
loaded PLGA nanoparticles, plasmid DNA-loaded PLA nanoparticles, coumarin-loaded PLA 
nanoparticles, indocyanine, cyclosporine (Cy-A)-loaded gelatin and cyclosporin (Cy-A)-
loaded sodium glycolate nanoparticles 
 
Fig.5: Schematic representation of the emulsification/solvent diffusion technique 
Salting out  
Salting out is based on the separation of a water miscible solvent from aqueous 
solution via a salting out effect. The salting out procedure can be considered as a 
modification of the emulsification/solvent diffusion. Polymer and drug are initially dissolved 
in a solvent such as acetone, which is subsequently emulsified into an aqueous gel containing 
the salting-out agent (electrolytes, such as magnesium chloride, calcium chloride, and 
magnesium acetate, or non- electrolytes such as sucrose) and a colloidal stabilizer such as 
polyvinylpyrrolidone or hydroxyethylcellulose. This oil/water emulsion is diluted with a 
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sufficient volume of water or aqueous solution to enhance the diffusion of acetone into the 
aqueous phase, thus inducing the formation of nanospheres
27
. The selection of the salting out 
agent is important, because it can play an important role in the encapsulation efficiency of the 
drug. Both the solvent and the salting out agent are then eliminated by cross-flow filtration. 
This technique used in the preparation of PLA, poly (methacrylic) acid, nanospheres leads to 
high efficiency and is easily scaled up. The main advantage of salting out is that it minimizes 
stress to protein encapsulants
35
. Salting out does not require an increase of temperature and 
therefore, may be useful when heat sensitive substances have to be processed
36
. The greatest 
disadvantages are exclusive application to lipophilic drugs and the extensive nanoparticle 
washing steps
37
. 
 
Fig.6: Schematic representation of the Salting out technique 
Preparation of nanoparticles by polymerization of a monomer  
To attain the desired properties for a particular application, suitable polymer 
nanoparticles must be designed, which can be done during the polymerization of monomers. 
Processes for the production of PNPs through the polymerization of monomers are discussed 
below. 
Emulsion polymerization  
Emulsion polymerization is one of the fastest methods for nanoparticle preparation 
and is readily scalable. The method is classified into two categories, based on the use of an 
organic or aqueous continuous phase. The continuous organic phase methodology involves 
the dispersion of monomer into an emulsion or inverse microemulsion, or into a material in 
which the monomer is not soluble (nonsolvent)
27
. Polyacrylamide nanospheres were 
produced by this method.As one of the first methods for production of nanoparticles, 
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surfactants or protective soluble polymers were used to prevent aggregation in the early 
stages of polymerization. This procedure has become less important, because it requires toxic 
organic solvents, surfactants, monomers and initiator, which are subsequently eliminated 
from the formed particles. As a result of the non-biodegradable nature of this polymer as well 
as the difficult procedure, alternative Approaches are of greater interest. Later, poly 
(methylmethacrylate) (PMMA), poly (ethylcyanoacrylate) (PECA), and 
poly(butylcyanoacrylate) nanoparticles were produced by dispersion via surfactants into 
solvents such as cyclohexane (ICH, class 2), n-pentane (ICH, class 3), and toluene (ICH, 
class 2) as the organic phase . In the aqueous continuous phase the monomer is dissolved in a 
continuous phase that is usually an aqueous solution, and the surfactants or emulsifiers are 
not needed. The polymerization process can be initiated by different mechanisms. Initiation 
occurs when a monomer molecule dissolved in the continuous phase collides with an initiator 
molecule that might be an ion or a free radical. Alternatively, the monomer molecule can be 
transformed into an initiating radical by high-energy radiation, including g-radiation, or 
ultraviolet or strong visible light. Chain growth starts when initiated monomer ions or 
monomer radicals collide with other monomer molecules according to an anionic 
polymerization mechanism. Phase separation and formation of solid particles can take place 
before or after termination of the polymerization reaction.  
 
Interfacial polymerization  
It is one of the well-established methods used for the preparation of polymer 
nanoparticles. It involves step polymerization of two reactive monomers or agents, which are 
dissolved respectively in two phases (i.e., continuous- and dispersed-phase), and the reaction 
takes place at the interface of the two liquids. Nanometer-sized hollow polymer particles 
were synthesized by employing interfacial cross-linking reactions as polyaddition and 
polycondensation or radical polymerization. Oil-containing nanocapsules were obtained by 
the polymerization of monomers at the oil/water interface of a very fine oil-in-water micro- 
emulsion. The organic solvent, which was completely miscible with water, served as a 
monomer vehicle and the interfacial polymerization of the monomer was believed to occur at 
the surface of the oil droplets that formed during emulsification. To promote nanocapsule 
formation, the use of aprotic solvents, such as acetone and acetonitrile was recommended. 
Protic solvents, such as ethanol, n-butanol and isopropanol, were found to induce the 
formation of nanospheres in addition to nanocapsules. Alternatively, water-containing 
nanocapsules can be obtained by the interfacial polymerization of monomers in water-in-oil 
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micro-emulsions. In these systems, the polymer formed locally at the water-oil interface and 
precipitated to produce the nanocapsule shell. 
 
Ionic gelation or coacervation of hydrophilic polymers  
Polymeric nanoparticles are prepared by using biodegradable hydrophilic polymers 
such as chitosan, gelatin and sodium alginate. Calvo and co-workers developed a method for 
preparing hydrophilic chitosan nanoparticles by ionic gelation.
38,39 
The method involves a 
mixture of two aqueous phases, of which one is the polymer chitosan, a di-block co-polymer 
ethylene oxide or propylene oxide (PEO-PPO) and the other is a poly anion sodium 
tripolyphosphate. In this method, positively charged amino group of chitosan interacts with 
negative charged tripolyphosphate to form coacervates with a size in the range of nanometer. 
Coacervates are formed as a result of electrostatic interaction between two aqueous phases, 
whereas, ionic gelation involves the material undergoing transition from liquid to gel due to 
ionic interaction conditions at room temperature. 
 
Fig.7: Schematic representation of ionic gelation method 
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CHARACTERIZTION OF NANO PARTICLES
4
  
The nanoparticles are generally characterized for size, density, electrophoretic 
mobility, angle of contact and specific surface area. Table.1 
 
Applications of Nanoparticulate Delivery Systems
7
 
 Tumor targeting using nanoparticulate delivery systems 
 Long circulating nanoparticles 
 Reversion of multi drug resistance in tumor cells 
 Nanoparticles for oral delivery of peptides and proteins 
 Targetting of nanoparticles to epithelial cells in the GI tract using ligands 
 Nanoparticles for gene delivery 
 Nanoparticles for drug delivery into the brain 
Future Opportunities and Challenges
2,3
 
1. Nanoparticles and nanoformulations have already been applied as drug delivery 
systems with great success; and nanoparticulate drug delivery systems have still greater 
potential for many applications, including anti-tumour therapy, gene therapy, AIDS therapy, 
radiotherapy, in the delivery of proteins, antibiotics, vaccines and as vesicles to pass the 
blood-brain barrier. 
PARAMETERS  CHARACTERISATION METHODS  
Partical size and size 
distribution  
Photon correlation spectroscopy (PCS), Laser defractrometry, 
Transmission electron microscopy, Scanning electron 
icroscopy(SEM), Atomic force microscopy(AFM), Mercury 
porositometry  
Charge determination   Laser Doppler Anemometry, Zeta potentiometer  
Surface hydrophobicity  Water contact angle measurements, Rose Bengal (dye) binding, 
Hydrophobic interaction chromatography, X-ray photoelectron 
spectroscopy 
Chemical analysis of  
surface  
 Static secondary ion mass spectrometry, Sorptometer  
Carrier drug interaction   FTIR, XRD, Differential Scanning Calorimetry  
Nanoparticle dispersion 
stability  
 Critical flocculation temperature  
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2. Nanoparticles provide massive advantages regarding drug targeting, delivery 
release and with their additional potential to combine diagnosis and therapy, emerge as one of 
the major tools in nanomedicine. The main goals are to improve their stability in the 
biological environment, to mediate the bio-distribution of active compounds, improve drug 
loading, targeting, transport, release and interaction with biological barriers. The cytotoxicity 
of nanoparticles or their degradation products remains a major problem and improvements in 
biocompatibility obviously are a main concern of future research. 
 
3. There are many technological challenges to be met, in developing the following 
techniques: 
 Nano-drug delivery systems that deliver large but highly localized quantities 
of drugs to specific areas to be released in controlled ways; 
 Controllable release profiles, especially for sensitive drugs; 
 Materials for nanoparticles that are biocompatible and biodegradable; 
 Architectures / structures, such as biomimetic polymers, nanotubes; 
 Technologies for self-assembly; 
 Functions (active drug targeting, on-command delivery, intelligent drug 
release devices/bio responsive triggered systems, self-regulated delivery 
systems, systems interacting with the body, smart delivery); 
 Virus-like systems for intracellular delivery; 
 Nanoparticles to improve devices such as implantable devices/nanochips for 
nanoparticle release, or multi reservoir drug delivery-chips; 
 Nanoparticles for tissue engineering; e.g. for the delivery of cytokines to 
control cellular growth and differentiation, and stimulate regeneration; or for 
coating implants with nanoparticles in biodegradable polymer layers for 
sustained release; 
 Advanced polymeric carriers for the delivery of therapeutic peptide/proteins 
(biopharmaceutics); 
 And also in the development of: Combined therapy and medical imaging, for 
example, nanoparticles for diagnosis and manipulation during surgery (e.g. 
thermotherapy with magnetic particles); 
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 Universal formulation schemes that can be used as intravenous, intramuscular 
or peroral drugs 
 Cell and gene targeting systems. 
 User-friendly lab-on-a-chip devices for point-of-care and disease prevention 
and control at home. 
 Devices for detecting changes in magnetic or physical properties after specific 
binding of ligands on paramagnetic nanoparticles that can correlate with the 
amount of ligand. 
 Better disease markers in terms of sensitivity and specificity. 
 
Sustained Release Drug Delivery System
40
 
 
Over the Past 30 years, as the expense and complications involved in marketing new 
drug entities have increased, with concomitant recognition of the therapeutic advantages of 
Sustained drug delivery, greater attention is being paid on development of oral sustained 
release drug delivery systems. The goal in designing sustained release drug delivery system is 
to reduce the frequency of the dosing, reducing the dose & providing uniform drug delivery. 
So, Sustained release dosage form is a dosage form that releases one or more drugs 
continuously in predetermined pattern for a fixed period of time, either systemically or 
locally to specified target organ. Sustained release dosage forms provide better control of 
plasma drug levels, less dosage frequency, less side effect, increased efficacy and constant 
delivery. 
 
 
Fig.8: Classification of Modified Release Drug Delivery System 
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Sustained release drug delivery system  
It includes any drug delivery system achieves release of drug over an extended period 
of time, which not depend on time. Hydrophilic polymer matrix is widely used for 
formulating a Sustained dosage form. The role of ideal drug delivery system is to provide 
proper amount of drug at regular time interval & at right site of action to maintain therapeutic 
range of drug in blood plasma. 
The IR drug delivery system lacks some features like dose maintenance, sustained 
release rate & site targeting. The oral Sustained drug delivery has some potential advantage 
like Sustained release rate & dose maintenance in plasma. The SR formulations have some 
swelling polymer or waxes or both which controls the release rate. The use of reservoir 
system is also well known for controlling release rate. 
 
Fg.9: Ideal Plasma Concentration Curves for Immediate Release, Zero Order Release, 
Sustained Release Drug Delivery System 
ADVANTAGES OF SUSTAIN RELEASE DOSAGE FORMS
41
 
1. Reduction in frequency of intakes. 
2. Reduce side effects. 
3. Uniform release of drug over time. 
4. Better patient compliance 
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DISADVANTAGES OF SUSTAINED RELEASE DRUG DELIVERY 
1. Increased cost. 
2. Toxicity due to dose dumping. 
3. Unpredictable and often poor in vitro-in vivo correlation. 
4. Risk of side effects or toxicity upon fast release of contained drug (mechanical 
failure,   chewing or masticating, alcohol intake). 
5. Increased potential for first- pass clearance. 
6. Need for additional patient education and counselling 
 
PRINCIPLE OF SUSTAINED RELEASE DRUG DELIVERY
42 
 
The conventional dosage forms release their active ingredients into an absorption pool 
immediately. This is illustrated in the following simple kinetic scheme. 
 
 
Dosage                     Kr                                  Target                                       Ke 
 
                        
 
 
From                Drug release                           Area                                   Elimination
 
Fig.10: Conventional dosage form release 
The absorption pool represents a solution of the drug at the site of absorption, and the 
term Kr, Ka and Ke are first order rate-constant for drug release, absorption and overall 
elimination respectively. Immediate drug release from a conventional dosage form implies 
that Kr>>>>Ka. Alternatively speaking the absorption of drug across a biological membrane 
is the rate-limiting step. For non-immediate release dosage forms, Kr<<<Ka i.e. the release of 
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drug from the dosage form is the rate limiting step. This causes the above Kinetic scheme to 
reduce to the following. 
 
Dosage                Kr            Absorption               Ka            Target                      Ke 
 
 
 
 
From            Drug release        Pool            Absorption        Area               Elimination  
Fig.11: Sustained release 
Essentially, the absorptive phase of the kinetic scheme become insignificant 
compared to the drug release phase. Thus, the effort to develop a non-immediate release 
delivery system must be directed primarily at altering the release rate. The main objective in 
designing a sustained release delivery system is to deliver drug at a rate necessary to achieve 
and maintain a constant drug blood level. This rate should be analogous to that achieved by 
continuous intravenous infusion where a drug is provided to the patient at a constant rate. 
This implies that the rate of delivery must be independent of the amount of drug remaining in 
the dosage form and constant over time. It means that the drug release from the dosage form 
should follows zero-order kinetics, as shown by the following equation: 
Kr° = Rate in = Rate out = Ke Cd Vd 
Where, 
Kr°= Zero-order rate constant for drug release-Amount/time 
Ke = First-order rate constant for overall drug elimination time
-1
 
Cd= Desired drug level in the body - Amount/volume, and 
Vd= Volume space in which the drug is distributed-Liters 
The value of Ke, Cd and Vd are obtained from appropriately designed single dose 
pharmacokinetic study. The equation can be used to calculate the zero order release rate 
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constant. For many drugs, however, more complex elimination kinetics and other factors 
affecting their disposition are involved. This in turn affects the nature of the release kinetics 
necessary to maintain a constant drug blood level. It is important to recognize that while zero-
order release may be desirable theoretically, non-zero-order release may be equivalent 
clinically to constant release in many cases. Sustained-release systems include any drug-
delivery system that achieves slow release of drug over an extended period of time. If the 
systems can provide some control, whether this being of a temporal or spatial nature, or both, 
of drug release in the body, or in other words, the system is successful at maintaining 
constant drug levels in the target tissue or cells, it is considered a controlled-release system. 
    
Formulation strategy for oral SRDDS
40
 
 Diffusion sustained system 
 Dissolution sustained system 
 Methods using ion exchange 
 Methods using osmotic pressure 
 pH independent formulation 
 Altered density formulation 
Mechanism of drug release
41
 
Diffusion is rate limiting Diffusion is driving force where the movement of drug 
molecules occurs from high concentration in the tablet to lower concentration in gastro 
intestinal fluids. This movement depends on surface area exposed to gastric fluid, diffusion 
pathway, drug concentration gradient and diffusion coefficient of the system 
 
Fig.12: Mechanism of drug release 
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In practice, we can follow either of the two methods, 
 The drug is formulated in an insoluble matrix; the gastric fluid penetrates the dosage 
form and dissolves the medicament and release the drug through diffusion. 
 The drug particles are coated with polymer of defined thickness so as the portion of 
drug slowly diffuse through the polymer to maintain constant drug level in blood  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 	
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2. LITERATURE REVIEW 
 
Ambike et al., 
43
 formulated the surface solid dispersions (SSD) of Simvastatin to improve 
the aqueous solubility and dissolution rate to facilitate faster onset of action. Simvastatin is a 
BCS Class II drug having low solubility (1.45μg/ml) and therefore low oral bioavailability 
(5%). SSDs of Simvastatin with two different superdisintegrants in three different drug–
carrier ratios were prepared by a coevaporation method. Surface solid dispersions were 
characterized by differential scanning calorimetry (DSC), powder x-ray diffractometry 
(PXRD), scanning electron microscopy (SEM), and infrared spectroscopy (IR) and evaluated 
for drug content, saturation solubility, pH-dependent solubility, solubility in biorelevant 
media (i.e., fasted-state simulated intestinal fluid [FaSSIF] and fed-state simulated intestinal 
fluid [FeSSIF]), in vitro dissolution, and in vivo studies by a Triton-induced 
hypercholestermia model in rats. DSC studies revealed that there was no interaction between 
drug and carrier, whereas the PXRD study demonstrated that there was a significant decrease 
in crystallinity of pure drug present in surface solid dispersions, which resulted in an 
increased dissolution rate of Simvastatin. 
 
Galindo-Rodriguez et al., 
44 
formulated and optimized Repaglinide (Rg) loaded Chitosan 
(CN) Nanoparticles as a sustained release. Repaglinide is an oral hypoglycemic agent of the 
meglitinide analogue; it acts by increasing insulin secretion but binds to different beta-cell 
receptor sites from Sulphonylureas. Chitosan, a polycationic polymer, comprising d-
glucosamine and N-acetyl-d glucosamine linked by b-(1, 4)-glycosidic bonds. Repaglinide 
loaded chitosan nanoparticles were prepared by solvent evaporation method in three different 
ratios. In this method weighed quantity of drug and polymer were dissolved in suitable 
organic solvent acetone and 2%  acetic acid (organic phase). This solution was added drop by 
drop to the aqueous phase of PVA and homogenized using homogenizer at 18000 rpm 
followed by magnetic stirring for 2-3 h. The formed Rg-CN nanoparticles were recovered by 
centrifugation at 25,000 rpm for 15 min followed by washing thrice with petroleum ether and 
lyophilized. The prepared nanoparticles were evaluated for particle size, Scanning Electron 
Microscopy (SEM), Fourier Transform Infrared spectroscopy study (FT-IR), percentage 
yield, drug entrapment and for in vitro release kinetics. Among the three different ratio 1:4 
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ratio shown high drug loading (11.22% w/w) and encapsulation efficiencies (97.0%) and 
nanoparticle recovery (86.40%) with nanosize. Scanning electron microscopy exposed that 
nanoparticles were spherical in shape with a nearly smooth surface morphology. Particle size 
was analyzed by Malvern particle size analyzer and shown 48-100 nm range. FT-IR study 
reveals that, there was no interaction between Repaglinide and polymers. Based on the in 
vitro study, Repaglinide released from prepared formulation was slow and sustained over 15 
days. Application of the in vitro drug release data to various kinetic equations indicated first 
order release, swelling and diffusion mechanism from Repaglinide nanoparticle. 
 
 Bathool et al., 
45 
formulated and evaluated the sustained release nanoparticles of 
Atorvastatin calcium. The nanoparticles were prepared by solvent evaporation method using 
Chitosan as a polymer. Low oral bioavailability of Atorvastatin calcium (14%) due to an 
extensive high first-pass effect makes it as prime target for oral sustained drug delivery. 
Weighed amount of drug and polymer were dissolved in suitable organic solvent DMSO and 
2% acetic acid as an organic phase. This solution is added drop wise to aqueous solution of 
Lutrol F68 and homogenized at 25000rpm followed by magnetic stirring for 4hrs. 
Nanoparticles were evaluated for its particle size, scanning electron microscopy (SEM), 
Fourier-Transform infrared spectroscopy (FTIR), percentage yield, drug entrapment and for 
in vitro release kinetics. Among the four different ratios, 1:4 ratio showed high drug loading 
and encapsulation efficiency. SEM studies shows that prepared nanoparticles were spherical 
in shape with a smooth surface. Particle size of prepared nanoparticles was found to be in the 
range between 142 nm to 221 nm. FTIR and DSC shows drug to polymer compatibility ruling 
out any interactions. In vitro release study showed that the drug release was sustained up to 7 
days. Hence, prepared nanoparticles proved to be promising dosage form for sustained drug 
delivery of atorvastatin reducing dosing frequency, thus increasing the patient compliance. 
 
Ramani et al., 
46 
formulated and evaluated Nanoparticles of Simvastatin. Simvastatin was 
formulated as immediate release. Simvastatin is a poorly soluble lipid lowering agent. It’s 
Water solubility is very low, approximately 30 μg/mL and poorly absorbed from the 
gastrointestinal (GI) tract. This work is an attempt to overcome the poor solubility and 
dissolution rate of simvastatin by using Nanosuspension technology. PVP and Tween 80 with 
Soybean Lecithin were used at different ratios as the surfactants. The formulations were done 
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by Emulsion-solvent evaporation method followed by freeze drying. The formulated 
nanoparticles were subjected to characterization studies like Particle size analysis, X-ray 
diffraction studies, Differential Scanning Colorimetry, Scanning electron microscopy and UV 
analysis. The dissolution test of tablets containing the nanometric drug flakes revealed that, 
within 30 minutes, 89.76% (w/w) of the Simvastatin in the tablet was dissolved. In 
comparison, the dissolution test of the conventional tablets revealed that under these testing 
conditions only 45.97% (w/w) Simvastatin was dissolved. This result demonstrates the 
significant advantage of simvastatin nanoparticles over the conventional particulate drug and 
the feasibility of the proposed method. 
 
 Suganeswari et al., 
47
 prepared the nanoparticles of Hypolipidaemic drug (Atorvastatin 
calcium) and Antihypertensive agent (Amlodipine besylate). Nanoparticles was prepared  by 
nanoprecipitation method using tribloere polymeric stabilizer (Pluronic F68) and poly (D,L-
lactide-co-glycolide) (PLGA) as a biodegradable polymer. Nanoparticles were characterized 
for size, drug loading, and in vitro release. Atorvastatin calcium is a second generation 3- 
hydroxy-3-methyl glutarylCoA reducatase inhibitor approved for clinical use as a lipid 
lowering agent. Atorvastatin calcium has poor oral bioavailability (12%) and serious adverse 
effects like rhabdomyolysis on chronic administration. Side effect of Atorvastatin was 
reduced 60% by combining with Amlodipine. The Amlodipine has potency to promote the 
activity of Atorvastatin. A biodegradable nanoparticulate approach was introduced here with 
a view to improving the efficacy and safety of Atorvastatin calcium. The nanoparticluate 
suspension of Amlodipine is to improve its absorption rate and therapeutic efficacy. 
 
Anilkumar j Shinde et al., 
48
 designed and evaluated Polylactic-co-glycolic acid 
nanoparticles containing Simvastatin. Simvastatin is a lipid lowering agent, and BCS class-II 
drug having low solubility and high permeability. Since Simvastatin undergoes extensive first 
pass extraction in the liver, the availability of the drug to the general circulation is low (< 
5%). Nanoparticles were prepared by precipitation-solvent deposition method using 3² full 
factorial design. From the preliminary trials, the constraints for independent variables X1 
(amount of PLGA) and X2 (amount of Pleuronic F-68) have been fixed. The prepared 
formulations were further evaluated for drug content, in vitro drug release pattern, short term 
stability and drug excipient interactions. The application of factorial design gave a 
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statistically systematic approach for the formulation and optimization of nanoparticles with 
desired particle size and high entrapment efficiency. Drug: polymer ratio and concentration 
of stabilizer were found to influence the particle size and entrapment efficiency of 
Simvastatin loaded PLGA nanoparticles. In vitro drug release study of selected factorial 
formulations (PS1, PS4, PS7) showed, 84.56%, 89.65 % and 73.46 % release respectively in 
24 hrs. The release was found to follow first order release kinetics with fickian diffusion 
mechanism for all batches. These results indicate that simvastatin loaded PLGA nanoparticles 
could be effective in sustaining drug release for a prolonged period. 
 
Vikram M. Pandya et al., 
49
 studied the optimization of Nanosuspension of Simvastatin. 
Simvastatin nanosuspension was prepared by nanoprecipitation. Prepared nanosuspension 
was evaluated for its particle size and in vitro dissolution study and characterized by 
Differential Scanning Calorimetry (DSC) and Scanning Electron Microscopy (SEM). A 2
3
 
factorial design was employed to study the effect of independent variables, amount of PVPK-
30 (X1), amount of SLS (X2) and organic to aqueous solvent ratio (X3) on dependent 
variables, particle size (nm) and time required to release 80% of drug (t80). The relationship 
between the dependent and independent variables was further elucidated using multiple liner 
regression analysis (MLRA). The obtained results showed that particle size (nm) and rate of 
dissolution has been improved when nanosuspension prepared with the higher concentration 
of PVPK-30 with the higher concentration of SLS and lower concentration of organic to 
aqueous ratio, The rate of dissolution of the optimized nanosuspension was enhanced (80% in 
20min), relative to micronized suspension of Simvastatin (7.03% in 20 min), mainly due to 
the formation of nanosized particles. These results indicate the suitability of 2
3
 factorial 
design for preparation of Simvastatin loaded nanosuspension significantly improved in vitro 
dissolution rate, and thus possibly enhance fast onset of therapeutic drug effect. 
 
Adlin jino nesalin J et al., 
50
 formulated and evaluated sustained release Nanoparticles of 
Flutamide. Flutamide, a substituted anilide, is a potent antiandrogenic that has been used in 
the treatment  of prostate carcinoma having short biological half-life of 5-6 hrs; Nanoparticles 
of Flutamide were formulated using chitosan polymer by ionic gelation technique. 
Nanoparticles of different core: coat ratio were formulated and analyzed for total drug 
content, loading efficiency, particle size and in vitro drug release studies. From the drug 
2. Literature review 
 
Department of Pharmaceutics, Madras Medical College  Page 27 
 
release studies it was observed that nanoparticles prepared with chitosan in the core: coat 
ratio 1:4 gives better sustained release for about 12 hrs as compared to other formulations. 
 
Anilkumar J shinde et al., 
51
 studied the effect of nanoparticle formulation on serum lipids 
in albino rats. The hypolipidemic effect was compared with a standard dose of Lovastatin, 
control and hyperlidemic control group. The rats were divided into four groups of six animals 
each. Test Treatment Group (TTG), Reference Treatment Group (RTG), Control Treatment 
Group (CTG) and Hyperlidemic Treatment Group (HTG). The treatment was given for 21 
days. Each treatment group received daily standard cholesterol diet, orally in the morning 
throughout 21 days to induce hyperlipidemia except control treatment group. Test 
formulation (TF), aqueous suspensions of Lovastatin (RF) administered oral dose was 1 mg 
per animal once a day (equivalent to 10 mg kg–1 per day). Blood samples were collected at 
predetermined time intervals viz., before treatment and after 5, 10, 15 and 21 days and serum 
cholesterol, triglycerides and high density lipoproteins were measured. Serum levels on days 
10 and 21 were compared using students paired t-test (p < 0.001). The results shows that 
plasma CH and TG levels were significantly lower (91.70±0.04 mg/dl, 145.50±0.03 mg/dl 
respectively) (p < 0.001) and HDL-CH levels were significantly higher (44.65±0.02 mg/dl, 
p< 0.001) in TTG compared to RTG. There was a significant decrease in serum cholesterol in 
nanoparticle formulation than standard drug. 
 
Vikram M Pandya et al., 
52 
formulated and evaluated Nanosuspension of Simvastatin and 
studied the effect of different stabilizer on the Simvastatin Nanosuspension. Simvastatin is 
BCS class-II drugs having low solubility and high permeability. Prepared nanosuspensions 
was evaluated for its particle size study, in vitro dissolution study and characterized by 
Screening Electron Microscopy (SEM). Nanosuspension prepared with the PVPK-30 has 
improved dissolution rate as compare to all other stabilizer because of decreases in particle 
size (417nm) as compared to micro suspension of Simvastatin. These study indicate the 
suitability of PVPK-30 as a stabilizer in the formulation of nanosuspension. 
 
Amir Dustgani et al., 
53
 synthesised and characterized novel biodegradable nanoparticles of 
Dexamethasone sodium phosphate. Nanoparticles prepared by ionic gelation method using 
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Chitosan as a biodegradable polymer. Biodegradable nanoparticulate carriers, have important 
potential applications for administration of therapeutic molecules. Chitosan based 
nanoparticles have attracted a lot of attention upon their biological properties such as 
biodegradability, biocompatibility and bioadhesivity. Drug containing nanoparticles were 
prepared with different amounts of drug. The mean size and size distribution of nanoparticles 
were measured by dynamic laser light scattering. The mean particle size, varied in the range 
of 250-350 nm. Values of loading capacity and loading efficiency varied between 33.7%-
72.2% and 44.5%-76.0% for prepared nanoparticles. 
 
Riddhi Dave and Rakesh Patel 
54
 prepared and evaluated chitosan nanoparticles containing 
Doxorubicin. Nanoparticles prepared by w/o emusion method. Polymeric nanoparticles are 
recently more investigated for controlled and targeted drug delivery. 11 batches of 
nanoparticles were prepared using different concentration of oil, span 20, Chitosan and TPP. 
Formulations were evaluated for particle size analysis. % entrapment, Scanning Electron 
Microscopy, Differential Scanning Calorimetry (DSC), Infrared (IR) spectrum and in vitro 
drug release. Formulation F3 selected as an optimized formulation based on highest 
entrapment efficiency (53.12%) with particle size of 210nm and in vitro drug release. 
 
Makarand Gambhirea, Mangesh Bhalekarb, Birendra Shrivastavaa 
55 
studied the solid 
lipid nanoparticle of Simvastatin to improve the oral bioavailability. Simvastatin is an 
antihyperlipidemic drug with poor oral bioavailability (<5%) due to the first pass metabolism.   
Simvastatin SLNs were developed using compritol 888 ATO by pre-emulsion followed by 
ultrasonication and characterized by photon correlation spectroscopy, DSC and XRD. 
Bioavailability studies were conducted in albino rats after oral administration of Simvastatin 
suspension and SLN. Stable Simvastatin SLNs having a mean particle size of 245 nm and % 
entrapment of 72.52% were developed. Simvastatin was dispersed in an amorphous state in 
the SLN. The results of the in-vitro drug release studies demonstrated significantly slow 
release of Simvastatin (37.08%) from SIMVA-SLN as compared to dispersion of pure drug 
(97.2%). The relative bioavailability of Simvastatin and Simvastatin hydroxy acid from SLN 
were increased by ~164% and ~207% respectively, compared with the reference Simvastatin 
suspension. Thus the study established that the oral bioavailability of Simvastatin could be 
improved by administration as SLN, presumably following digestion of constituting lipids 
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and co-absorption through lymphatic transport. The obtained results are indicative of SLNs as 
potential carriers for improving the bioavailability of poorly bioavailable drugs such as 
Simvastatin by minimizing first pass metabolism. 
 
Pankaj et al., 
56 
developed bi-layer tablets of Simvastatin using hydrophilic and or 
hydrophobic polymers. Simvastatin is a hypolipidemic drug used to control elevated 
cholesterol, or hypercholesterolemia. Simvastatin is a member of the statin class of 
pharmaceuticals, is a synthetic derivate of a fermentation product of Aspergillus terreus. The 
aim of present study was to prepare Simvastatin sustained release bilayer tablet by wet 
granulation method using hydrophilic and or hydrophobic polymers. Tablet is an important 
area of research in the field of drug delivery, because they the ability to deliver the wide 
range of drug for sustained period of time and therefore the dose and frequency of 
administration would be reduced hence increasing patient compliance. The formulated 
uncoated tablet of Simvastatin is evaluated successfully within the evaluation parameters 
which suggest that the tablet have better therapeutic level in systematic circulation. 
 
Athul P.V 
57
 formulated and characterized nanosuspension of Simvastatin (poorly soluble 
drug) by high pressure homogenization method to improve its dissolution characteristics and 
therapeutic activity. The prepared nanosuspensions were evaluated for DSC, Zeta potential 
analysis, SEM, solubility, in vitro drug release studies and in-vivo pharmacodynamic studies. 
DSC curves obtained confirms the transfer of drug crystalline form to amorphous form. 
Solubility studies and in-vitro drug release studies showed that the prepared nanosuspension 
has increased solubility and dissolution rate compared to pure drug. The in-vivo 
pharmacological studies showed that the nanosuspension of drug has increased anti 
hyperlipidemic activity compared to the pure drug. The technology was easy to scale up and 
requires less sophistication, the method can be extended to various poorly water soluble 
drugs. 
 
Gambhire M. S. et al., 
58
 described a Box-behnken design to optimize the formulation of 
Simvastatin (SIMVA) loaded solid lipid nanoparticles by pre-emulsion ultrasonication 
technique. The variables drug: lipid ratio, percentage of lipid phase surfactant and sonication 
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time were studied at three levels and arranged in a Box-behnken design, to study the 
influence on response variables particle size and % entrapment efficiency (%EE). From the 
statistical analysis of data, polynomial equations were generated. The physical characteristics 
of SIMVA-SLN were evaluated using particle size analyzer, differential scanning calorimetry 
and X-ray diffraction. The results of optimized formulation showed average particle size of 
245 nm and a drug entrapment of 72.52 %. The in-vitro drug release study of SIMVA-SLN 
using modified Franz diffusion cell showed significantly low release of Simvastatin (37.08%) 
than dispersion of pure drug (97.2 %). 
 
 Maravajhala vidyavathi, Neelam venkata ramana 
59
 designed and evaluated controlled 
release microspheres of Simvastatin, using ethylcellulose as controlled release polymer. 
Simvastatin – ethylcellulose microspheres were prepared by water-in-oil-in-oil double 
emulsion solvent diffusion method and evaluated for entrapment efficiency, in vitro drug 
release behavior, particle size and size distribution. The formula was optimized by changing 
the polymer-drug ratio, surfactant concentration for secondary emulsion process and stirring 
speed of emulsification process. The designed microspheres were spherical, free flowing and 
size distribution was between 24-48 μm. The entrapment efficiency and percentage yield 
were 83.67% & 84.31% respectively. The drug release was controlled for 12h. The in vitro 
release profiles from optimized formulations were applied on various kinetic models. The 
best fit with the highest correlation coefficient was observed in Higuchi model, indicated that 
the release is diffusion controlled mechanism. Absence of drug-polymer interaction was also 
evidenced by IR & DSC thermograms. In vivo pharmacodynamics study of the optimized 
formulation proved that prolongation of drug release by presently designed microspheres. 
 
B. Agaiah Goud et al., 
60
 developed mucoadhesive buccal tablets of Simvastatin using 
mucoadhesive polymers. Simvastatin has short biological half-life (3hr), high first-pass 
metabolism and poor oral bioavailability (5%), hence an ideal candidate for buccal delivery 
system. The tablets were prepared by direct compression technique using carbopol-934, 
sodium carboxy methyl cellulose (Na CMC) and hydroxyl propyl methyl cellulose (HPMC) 
as mucoadhesive polymers. Formulations were evaluated for mass variation, hardness, 
friability, drug content, swelling studies, erosion studies, in-vivo residence time, in-vitro 
release studies in pH 7.0 phosphate buffer with 0.5% SDS and ex-vivo permeation studies 
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through porcine buccal mucosa. Formulation FS5 and FH5 exhibited controlled drug release 
(8hr). Formulation FS5 selected as optimized formulation based on physicochemical 
parameters and ex-vivo permeation studies and follows zero order drug release. FTIR studies 
show no evidence on interaction between drug, polymers and other excipients. The results 
indicate that suitable bioadhesive buccal tablets for Simvastatin with desired in-vivo 
residence time and controlled release could be prepared. 
 
BasuvanBabu et al., 
61
 developed single-unit of oral sustained release dosage form 
Simvastatin (SS) have been prepared by the wet granulation method. The hydrophilic matrix 
was prepared with xanthan gum with additives MCC PH101. On the in vitro drug release was 
studied. The studies indicated that the drug release can be modulated by varying the 
concentration of the polymer and fillers. Various pharmacokinetic parameters including 
AUC0–t, AUC0–∞, Cmax, Tmax, T1/2, and elimination rate constant (Ke) were determined 
from plasma concentration of both formulations of test (Simvastatin 0.7 mg tablets) and 
reference (Simvastatin 1.4 mg tablets). The extent of absorption of drug from the sustained 
release tablets was significantly higher than that for the marketed Simvastatin tablet because 
of lower elimination and longer half-life. Various pharmacokinetic parameters including 
AUC0-t, AUC0-∞, Cmax, Tmax, T1/2, and Ke were determined from plasma concentration 
of both Sustained and Immediate release tablets. 
 
B.Brahmaiah et al., 
62
 prepared and evaluated the mucoadhesive microspheres of 
Simvastatin. Simvastatin microspheres were prepared by orifice-ionotropic gelation method 
using polymers such as HPMC (K 100 M), carbopol 940P, sodium CMC, guar gum, sodium 
alginate, ethyl cellulose, methyl cellulose and xanthan gum. Totally 15 different formulations 
of Simvastatin were prepared by using the above polymers. The microspheres were 
characterized for drug content, entrapment efficiency, mucoadhesive property by in vitro 
wash-off test and in-vitro drug release. The formulation F10 was selected as an ideal 
formulation based on the in vitro release profile which shows an extended drug release of 
97.11% upto 8 hours in phosphate buffer of pH 7.0. Surface morphology (SEM analysis) and 
drug-polymer interaction studies (FT-IR analysis) were performed only for the ideal 
formulation, F10. The microspheres were smooth and elegant in appearance showed no 
visible cracks as confirmed by SEM and FT-IR studies indicated the lack of drug-polymer 
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interactions in the ideal formulation, F10. The in vitro release data of all microsphere 
formulations were plotted in various kinetic equations to understand the mechanisms and 
kinetics of drug release. The ideal formulation, F10 followed Higuchi kinetics and value of 
"n," is calculated to be 0.86 indicated that the drug release shows non-fickian diffusion. 
 
Singla N. et al., 
63
 compared the single dose oral bioavailability of two formulations of 
Simvastatin in albino rats. Plasma was analyzed for Simvastatin using a sensitive, 
reproducible, accurate and validated LC-MS/MS method. Pharmacokinetic parameters 
including AUC0-t, AUC0-∞, Cmax, Tmax, and t1/2 were determined from plasma 
concentration for both formulations. Self-emulsifying formulation of Simvastatin showed a 
significant improvement in bioavailability (1.5 fold) as compared with the conventional 
tablets. 
 
P.Sandhya et al.,
64 
formulated Hydrogel based tablets of Simvastatin using hydropropyl 
methyl cellulose(different grades), guar gum and carbopal-934-P studied release kinetic, to 
attained a near zero order release and to increaseed the bioavalability upto 95%. In-vitro 
dissolution studies were carried out using USP type 2 dissolution test apparatus. The release 
of drug followed a typical Higuchian pattern. Hydrogel based tablets formulated employing 
hydroxyl propyl methyl cellulose, guar gum and carbopal-934-P slow release of Simvastatin 
over period of 12 h and were found suitable for maintenance portion of oral controlled release 
tablets. Simvastatin release from these tablets were diffusion controlled and followed zero 
order kinetics after a lag time of 1h. The most successful of the study, exhibited drug release 
pattern very close to theoretical release profile. A decrease in release kinetics of the drug was 
observed. 
 
Ana G Luque-Alcaraz et al., 
65 
prepared and characterized Chitosan Nanoparticles 
containing Nobiletin. Nobiletin is a polymethoxy flavonoid with a remarkable 
antiproliferative effect. In order to overcome its low aqueous solubility and chemical 
instability, the use of nanoparticles as carriers has been proposed. This study explores the 
possibility of binding Nobiletin to Chitosan nanoparticles, as well as to evaluate their 
antiproliferative activity. The association and loading efficiencies are 69.1% and 70%, 
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respectively. The formation of an imine bond between Chitosan amine groups and the 
carbonyl group of Nobiletin, via Schiff-base, is proposed. Nobiletin-loaded Chitosan 
nanoparticles exhibit considerable inhibition (μg/ml) of cancerous cells, revealing their great 
potential for applications in cancer chemotherapy. 
 
A.A. Kharia et al., 
66
 formulated and evaluated nanoparticles of Acyclovir by using different 
hydrophilic polymers. Acyclovir was selected as a suitable drug for gastroretentive 
nanoparticles due to its short half-life, low bioavailability, high frequency of administration, 
and narrow absorption window in stomach and upper part of GIT. The nano-precipitation 
method was used to prepare nanoparticles so as to avoid both chlorinated solvents and 
surfactants to prevent their toxic effect on the body. Nanoparticles of acyclovir were prepared 
by using hydrophilic polymers such as bovine serum albumin, chitosan, and gelatin. The 
prepared formulations were then characterized for particle size, polydispersity index, zeta 
potential, loading efficiency, encapsulation efficiency and drug-excipient compatibility. The 
prepared nanoparticulate formulations of Acyclovir with different polymers in 1:1 ratio have 
shown particle size in the range of 250.12-743.07 nm, polydispersity index (PDI) in the range 
of 0.681-1.0, zeta potential in the range of -14.2 to +33.2 mV, loading efficiency in the range 
of 8.74-17.54%, and entrapment efficiency in the range of 55.7%-74.2%. Nanoparticulate 
formulation prepared with Chitosan in 1:1 ratio showed satisfactory results i.e. average 
particle size 312.04 nm, polydispersity index 0.681, zeta potential 33.2 mV, loading 
efficiency 17.54%, and entrapment efficiency 73.4%. FTIR study concluded that no major 
interaction occurred between the drug and polymers used in the present study. 
 
 Bhavisha Rabadiya et al., 
67
 studied the drug polymer interaction of drug Simvastatin (SV) 
with different polymers like Chitosan, glycin and beta cyclodextrin(β-CD),The analytical 
techniques used for the purpose are Fourier Transform Infrared Spectroscopy(FTIR) and 
Differential Scaning Calorimeter(DSC) to characterize any drug polymer interactions and 
formation of inclusion complex. The complexes were prepared by simple kneading technique 
and were evaluated for phase solubility and aqueous solubility. The FTIR and DSC study 
indicate no interaction occurs between drug- polymers and revealed that no endothermic and 
characteristic diffraction peaks of SV was observed in the inclusion complexes. The study 
indicated the conversion of crystalline form of SV into the amorphous form. Aqueous 
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solubility profiles were markedly increased in inclusion complexes, compared with the drug 
alone and physical mixture this study is done so that future formulations can be prepared 
based on these results. Simvastatin is compatible with polymers and solubility of drug was 
increase by formation of inclusion complex with beta cyclodextrin(β-CD). 
 
Parmar et al., 
68 
formulated Strategy for Dissolution Enhancement of Simvastatin. 
Simvastatin is lipid lowering drug which is known as HMG CoA reductase. The objective of 
the study was to increase the solubility of poorly water soluble drug, namely Simvastatin, by 
the formation of solid dispersion and complex and also using the microwave induction 
technique on these formations. For solid dispersion method dispersion carrier used were 
poloxamer 407 and gelucire 44/14. The fusion method was used to prepare the dispersions. 
For inclusion complexation method β-cyclodextrin derivative of cyclodextrin was used to 
prepare complex with drug. Kneading method was used for formulation. After completion of 
these two techniques these polymers were used for the microwave induced fusion method. 
All the ratio of drug and polymer were used to heat for different time interval. These samples 
were used for solubility measurement. In the solid dispersion technique, Simvastatin show 
higher increase in solubility with gelucire 44/14 in the ratio of 1:5 as compare to poloxamer 
407. In the microwave induced fusion method simvastatin show higher solubility with 
simvastatin with gelucire 44/14 after 10 mins time interval as compare to poloxamer 407 and 
β-cyclodextrin. Solubility of Simvastatin increased higher with gelucire 44/14 by using 
microwave induced fusion method as compare to other technique. By using gelucire 44/14 
with Simvastatin it show 94% increase in solubility of Simvastatin as compare to pure drug in 
water. 
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3. AIM AND PLAN OF WORK 
 
 
 To formulate Simvastatin loaded Chitosan Nanoparticle  
 
 To carry out the Characterization of  Simvastatin Nanoparticles  
 
 Identification and confirmation of purity of drug by UV Spectrophotometry. 
 
 Pre-formulation studies  
 
 Drug polymer compatibility studies 
 
 Evaluation of Nanoparticles 
   a) Entrapment efficiency 
  b) Loading efficiency 
  c) Percentage yield 
  d) Drug content 
   e) Solubility studies  
f) Drug particle size analysis by SEM  
g) In-vitro drug release studies 
h) In-vivo studies of nanoparticles as per the CPCSEA guidelines. 
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SIMVASTATIN LOADED CHITOSAN NANOPARTICLES 
 
 
          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pre- formulation studies Simvastatin Nanoparticles 
 Standard curve 
of Simvastatin 
 
 Fourier 
transformation 
Infrared 
spectroscopy 
 
 Optimization of formulation 
 PCS 
 SEM 
 FTIR of optimized formulation F3 
 DSC 
 XRD 
 In-vitro drug release 
 Kinetics of drug release 
 In-vivo drug release 
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4. RATIONALE OF STUDY
45, 48, 69, 70
 
 
 The main objective of this work is to design and develop biocompatible 
Simvastatin nanoparticle for medical applications using natural polymer. 
 
 Simvastatin is a better hypolipidemic drug which is used to treat various 
cardiovascular diseases. 
 
 The main objective is to enhance the solubility, bioavailability and half-life of 
the drug. To reduce the toxicity, unwanted side effects and significant 
reduction of the dosage of the drug by conjugating the drug with chitosan 
which is used as the carrier. 
 
 Chitosan is used as a polymer because of its advantages like biodegradability, 
biocompatibility, non-toxicity, non-immunogenicity, low cost, mucoadhesive 
and also act as stabilising agent. 
 
 Simvastatin Nanoparticles are prepared by Nanoprecipitation method. 
Surfactants are not necessary which might influence the surface characteristics 
or cause toxic effects. 
  
 Statins- Atorvastatin, Lovastatin, Pravastatin and simvastatin have been found 
to reduce deaths from heart attack among patients with history of heart disease 
or risk factor for heart disease, such as diabetes and high blood pressure. 
 
 No risk of cancer 
 
 
 
 
 
 
4. Rationale of the study 
 
Department of Pharmaceutics, Madras Medical College  Page 38 
 
 
 	

5. Disease Profile 
 
Department of Pharmaceutics, Madras Medical College  Page 38 
 
5. DISEASE PROFILE 
 
5.1 ATHEROSCLEROSIS
71
 
 
Atherosclerosis (or arteriosclerotic vascular disease) is a condition where the arteries 
become narrowed and hardened due to an excessive build-up of plaque around the artery 
wall. The disease disrupts the flow of blood around the body, posing serious cardiovascular 
complications. 
 
Arteries contain an endothelium, a thin layer of cells that keeps the artery smooth and 
allows blood to flow easily. Atherosclerosis starts when the endothelium becomes damaged, 
allowing LDL cholesterol to accumulate in the artery wall. The body sends macrophage white 
blood cells to clean up the cholesterol, but sometimes the cells get stuck there at the affected 
site. Over time this results in plaque being built up, consisting of bad cholesterol (LDL 
cholesterol) and macrophage white blood cells. 
 
The plaque clogs up the artery, disrupting the flow of blood around the body. This 
potentially causes blood clots that can result in life-threatening conditions such as heart 
attack, stroke and other cardiovascular diseases. The condition can affect the entire artery 
tree, but mainly affects the larger high-pressure arteries. 
 
Fig.13: A represents a healthy artery. B shows an artery with plaque build-up 
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Signs 
 The first signs of atherosclerosis can begin to develop during adolescence, with 
streaks of white blood cells appearing on the artery wall. 
 
Symptoms 
  The patient feels and describes, such as pain and rashes. The symptoms of the disease 
depend on which arteries are affected: 
 
Carotid Arteries - these arteries provide blood to the brain, when the blood supply is limited 
patients can suffer stroke and may experience: 
 Weakness 
 Difficulty breathing 
 Headache 
 Facial numbness 
 Paralysis 
 
Coronary Arteries - these arteries provide blood to the heart, when the blood supply to the 
heart is limited it can cause angina and heart attack, symptoms include: 
 Vomiting 
 Extreme anxiety 
 Chest pain 
 Coughing 
 Feeling faint 
 
Renal Arteries- these supply blood to the kidneys; if the blood supply becomes limited, there 
is a serious risk of developing chronic kidney disease, and the patient may experience: 
 Loss of appetite 
 Swelling of the hands and feet 
 Difficulty concentrating 
 
Peripheral arterial disease - the arteries to the limbs, usually the legs, are blocked. The most 
common symptom is leg pain, either in one or both legs, usually in the calves, thighs or hips. 
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The pain may be described as one of heaviness, cramp, or dullness in the leg muscles. Other 
symptoms may include: 
 Hair loss on legs or feet 
 Male impotence (erectile dysfunction) 
 Numbness in the legs 
 The colour of the skin on the legs change 
 The toenails get thicker& Weakness in the legs 
 
Causes of Atherosclerosis 
The condition is caused by macrophage white blood cells and fat that accumulates in 
arteries -the white blood cells are originally sent by the body's immune system to clean up 
LDL cholesterol pockets. When they stick to an artery they secrete a molecule called netrin-1, 
this stops normal migration of the macrophages out of the arteries. As a result, what you have 
left is a mixture of clumped up cholesterol pockets and white blood cells, this is the plaque 
that can disrupt blood flow. 
 
Certain factors that can damage the inner area of the artery (endothelium) and can trigger 
atherosclerosis include: 
 High Blood Pressure 
 High levels of cholesterol 
 Smoking 
 High levels of sugar in the blood 
Areas of the artery that are damaged are likely to have plaque build-up which can 
eventually break open. When the plaque breaks open, blood cell fragments called 
thrombocytes (or platelets) accumulate at the affected area. These fragments can then stick 
together, forming blood clots. 
 
Diabetes - patients with poorly-controlled diabetes, who frequently have excess blood 
glucose levels, are much more likely to develop atherosclerosis. 
 
Genetics - people with a parent or sibling who has/had atherosclerosis and cardiovascular 
disease have a much higher risk of developing atherosclerosis than others. 
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Air pollution - in 2007, researchers from the University of California in Los Angeles linked 
exposure to diesel exhaust particles in air pollution to a higher risk of bad cholesterol build-
up in the arteries.  
 
Diagnosing Atherosclerosis 
Those who are at risk of developing atherosclerosis should be tested, as the symptoms 
don't show until cardiovascular disease develops. A diagnosis will be based on the medical 
history of a patient, test results and a physical exam. 
 
Blood tests - measure sugar, fat and protein level in blood. If there are high levels of fat and 
sugar it can be an indicator the risk of developing the condition. 
 
Physical exam 
 The doctor will listen to the arteries using a stethoscope to see if there is an unusual 
"whooshing" sound reflecting turbulence of flow - called a bruit. If a bruit is heard 
then it can mean there is plaque obstructing blood flow. 
 There may also be a very weak pulse below the area of the artery that has narrowed. 
Sometimes there is no detectable pulse. 
 An affected limb may have abnormally low blood pressure 
 There may be signs of an aneurysm (pulsating bulge) behind the patient's knee or in 
their abdomen 
 Where blood flow is restricted, wounds may not heal properly 
 
Ultrasound - an ultrasound scanner is able to create a picture of the inside of  body using 
sound waves. It can check blood pressure at distinct parts of the body; changes in pressure 
indicate where arteries may have obstruction of blood flow. 
 
Computed tomography (CT) scan - A CT scan uses X-ray images to create detailed 
pictures of the inside parts of the body. It can be used to find arteries that are hardened and 
narrowed. 
 
 
 
5. Disease Profile 
 
Department of Pharmaceutics, Madras Medical College  Page 42 
 
TREATMENT FOR ATHEROSCLEROSIS 
 
 Lifestyle changes 
 Maintain a healthy weight. 
 Medication or surgery. 
 
Lifestyle Changes- The changes will focus on weight management, physical activity and a 
healthy diet. To recommend eating foods high in soluble fiber and limited intake of saturated 
fats, sodium and alcohol. 
 
Medication – Use of medications to prevent the build-up of plaque or to help prevent blood 
clots (antiplatelet). Other medications such as statins may be prescribed to lower cholesterol 
and Angiotensin-converting enzyme (ACE) inhibitors to lower blood pressure. 
 
Surgery - Severe cases of atherosclerosis may be treated by surgical procedures, such as 
angioplasty or coronary artery bypass grafting (CABG). 
Angioplasty involves expanding the artery and opening the blockage, so that the blood can 
flow through properly again. CABG is another form of surgery that can improve blood flow 
to the heart by using arteries from other parts of the body to bypass a narrowed coronary 
artery. 
 
Prevention of Atherosclerosis 
The best way to prevent atherosclerosis is to eliminate any risk factors you might 
have. The best way to do this is by living a healthy lifestyle. 
Diet- To avoid saturated fats, they increase bad cholesterol level. The following foods are 
high in unsaturated fats and can help keep bad cholesterol levels down: 
 olive oil 
 avocados 
 walnuts 
 oily fish 
 nuts 
 seeds 
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Exercise- exercise will improve fitness level and lower blood pressure. For overweight 
patients, exercise can help to lose weight through activities such as walking, swimming, and 
cycling. 
 
Smoking- this is one of the major risk factors for atherosclerosis, it also raises blood 
pressure.  
 
Flu vaccine -Medicine in Australia said that the flu vaccination may reduce the risk of heart 
attack by 50% in middle aged individuals with narrowed arteries. 
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5.2 DYSLIPIDEMIA
72, 73 
 
DEFINITION 
Dyslipidemia is an abnormal amount of lipids (cholesterol/fat) in the blood. In 
developed countries, most dyslipidemias are hyperlipidemias; that is elevation of lipids in the 
blood. This is often due to diet and lifestyle. Prolonged elevation of insulin levels can also 
lead to dyslipidemia. 
 
TYPES OF DYSLIPIDEMIA 
Table.2: Types of Dislipidemia 
 Increase Decrease 
LIPID  Hyperlipidemia 
-Hypercholesterolemia: due 
to defect of chromosome 19. 
-Hyperglyceridemia: 
glycerides 
-Hypertriglyceridemia 
triglycerides 
 
 Hypolipidemia 
 Hypercholesterolemia 
LIPOPROTEINS  Hyperlipoproteinemia: 
lipoprotein(usually LDL) 
 Hyperchylomicronemia 
Chylomicrons 
 Hypolipoproteinemia 
Lipoprotein 
 Abetalipoprotenemia: β-
lioproteins 
 Tangier disease: HDL 
BOTH Combined hyperlipidemia: both 
LDL and triglycerides 
 
 
ETIOLOGY 
 Primary and secondary causes contribute to dyslipidemia. 
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PRIMARY CAUSES 
 Primary causes are single and multiple gene mutations that result in either 
overproduction or defective clearance of TG and LDL cholesterol or in underproduction or 
excessive clearance of HDL. 
 
SECONDARY CAUSES 
 Secondary causes contribute to most cases of dyslipidemia in adults. The most 
important secondary causes in developed countries are a sedentary lifestyle with excessive 
dietary intake of saturated fat. Cholesterol and trans fat. 
 
 Diabetes is an especially significant secondary cause because patients tend to have an 
atherogenic combination of high TGs: high small, dense LDL fractions; and low HDL 
(diabetic dyslipidemia). Patients with type 2 diabetes are especially at risk. 
 
SIGNS AND SYMPTOMS 
 Dyslipidemia itself usually causes no symptoms but can lead to symptomatic vascular 
diseases including coronary artery disease (CAD) and peripheral arterial disease. 
 
 High levels of TGs (<1000mg/dl) can cause acute pancreatitis. 
  
 High levels of LDL can cause eyelid xanthelasmas; arcuscorneae; and 
tendinousxanthomas at the Achilles elbow and knee tendons and over metacarpophalangeal 
joints. 
 
 Severe hypertriglyceridemia (>2000mg/dl) can give retinal arteries a creamy white 
appearance (lipemiaretinalis). 
 
 Extremely high lipid levels give a lactescent (milky) appearance to plasma. 
 Symptoms include Parasthesias, Dyspnea and Confusion. 
 
DIAGNOSIS 
 Diagnosis is by measuring plasma levels of total cholesterol, TGs and individual 
lipoproteins 
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Diagnostic values 
Table.3: Cholesterol value 
Total cholesterol 
(U.S. and some other 
countries) 
Total cholesterol* 
(Canada and most of 
Europe) 
Cardiovascular 
disease 
Below 200 mg/dL Below 5.2 mmol/L Desirable 
200-239 mg/dL 5.2-6.2 mmol/L Borderline high 
240 mg/dL and above Above 6.2 mmol/L High 
 
 
Table.4: Low density Lipoproteins value 
LDL cholesterol 
(U.S. and some other 
countries) 
LDL cholesterol* 
(Canada and most of 
Europe) 
 Cardiovascular disease 
Below 70 mg/dL Below 1.8 mmol/L Ideal for people at very high risk of 
heart disease 
Below 100 mg/dL Below 2.6 mmol/L Ideal for people at risk of heart 
disease 
100-129 mg/dL 2.6-3.3 mmol/L Near ideal 
130-159 mg/dL 3.4-4.1 mmol/L Borderline high 
160-189 mg/dL 4.1-4.9 mmol/L High 
190 mg/dL and above Above 4.9 mmol/L Very high 
 
 
Table.5: High Density Lipoproteins value 
HDL cholesterol 
(U.S. and some other 
countries) 
HDL cholesterol* 
(Canada and most of 
Europe) 
Cardiovascular 
disease  
Below 40 mg/dL (men) 
Below 50 mg/dL (women) 
Below 1 mmol/L (men) 
Below 1.3 mmol/L (women) 
Poor 
40-49 mg/dL (men) 
50-59 mg/dL (women) 
1-1.3 mmol/L (men) 
1.3-1.5 mmol/L (women) 
Better 
60 mg/dL and above 1.6 mmol/L and above Best 
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Table.6: Triglyceride value 
Triglycerides 
(U.S. and some other 
countries) 
Triglycerides* 
(Canada and most of 
Europe) 
 Cardiovascular 
disease 
Below 150 mg/dL Below 1.7 mmol/L Desirable 
150-199 mg/dL 1.7-2.2 mmol/L Borderline high 
200-499 mg/dL 2.3-5.6 mmol/L High 
500 mg/dL and above Above 5.6 mmol/L and above Very high 
 
SCREENING 
 A Fasting profile (TC, TG, HDL, LDL-C) should be obtained in all adults >20 years 
and should repeated every five years. 
 
MANAGEMENT 
 
 The main goal of dyslipidemia management is to maintain blood cholesterol level 
within the normal range as possible. 
 
 Lifestyle modification focusing on the reduction of saturated fat and 
cholesterol intake 
 Weight loss 
 Increased physical activity 
 Smoking cessation 
 
TREATMENT 
 
DRUGS -FOUR CLASSES OF LIPID LOWERING DRUGS ARE 
 
 HMG CoA reductase inhibitor(statins) 
 Fibrates(gemfibrozil, clofibrate,fenofibrate) 
 Niacin(nicotinic acid) 
 Bile acid binding resins (colestipol.cholestyramine). 
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6. DRUG PROFILE 
6.1SIMVASTATIN
74, 75 
Chemical structure 
  
Chemical name 
 (1S, 3R, 7S, 8S, 8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-
1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate. 
Molecular formula             : C25H38O5 
Molecular weight   : 418.566 g/mol 
Description    : a white or almost white crystalline powder. 
Melting point              : melts between 135 and 138
o
c 
Solubility   : very soluble in dichloromethane;  
       freely soluble in ethanol (95%); 
       practically insoluble in water. 
Loss on drying  : not more than 0.5%, determined on 1.0g by drying in  
                 an oven at 60
o
c for 3 hrs under high vaccum. 
Sulphated ash  : not more than 0.1% 
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Mechanism of action 
 Simvastatin is a prodrug and is hydrolysed to its active β-hydroxy acid form, 
Simvastatin acid after its administration. 
 Simvastatin is a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzymeA 
(HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-
CoA to mevalonate, an early and rate limiting step in biosynthetic pathway for 
cholesterol. 
 In addition, Simvastatin reduces VLDL and TG and increases HDL-C. 
Pharmacokinetics 
Absorption   : oral absorption of Simvastatin is found to be 42.5% 
Bioavailability            : 5% 
Half-life   : 3 hours 
Plasma protein binding : ~95% bound to plasma proteins. 
Metabolism   : extensively hepatic; undergoes metabolism by  
      CYP3A4. 
Excretion   : renal 13%; fecal 60% 
Therapeutic indications 
 The primary uses of Simvastatin are for the treatment of dyslipidemia. 
 It is also used for the prevention of cardiovascular disease. 
 Used in homozygous familial hypercholesterolemia. 
Route/dosage 
For hyperlipidemia 
Adult dose       - 10 to 20 mg orally once in the evening 
Children less than 10 years     - 5 mg once daily in evening. 
Cardiovascular risk reduction     - 10 to 20 mg orally once in the evening. 
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Contra indications 
Simvastatin is contraindicated in pregnancy, breast feeding and liver diseases. It is 
also contra indicated with amlodipine. 
Adverse effects 
 Abdominal pain, diarrhoea, indigestion and a general feeling of weakness. 
Drug interactions 
 CYP3A4 inhibitors like Itraconazole, Ketoconazole, Erythromycin, Amiodaron , etc. 
decreases the metabolism of simvastatin. 
 Grape fruit contains furanocoumarin which slows down the metabolism of 
simvastatin. 
Combination with other drugs 
 Simvastatin+Ezetimibe 
 Simvastatin+Niacin. 
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7. EXCIPIENT PROFILE 
7.1CHITOSAN
76, 77
 
 Nonproprietary names  
 BP: Chitosan hydrochloride 
 PhEur: Chitosani hydrochloridum 
 Synonyms 
2-Amino-2-deoxy-(1,4)-b-D-glucopyranan; deacetylated chitin; deacetylchitin; b-1,4-
poly-D-glucosamine; poly-D-glucosamine; poly-(1,4-b-D-glucopyranosamine).  
Chemical name and CAS registry number  
Poly-b-(1, 4)-2-Amino-2-deoxy-D-glucose (9012-76-4)  
Empirical formula and molecular weight  
Partial deacetylation of chitin results in the production of chitosan, which is a 
polysaccharide comprising copolymers of glucosamine and N-acetylglucosamine. Chitosan is 
the term applied to deacetylated chitins in various stages of deacetylation and 
depolymerization and it is therefore not easily defined in terms of its exact chemical 
composition.  
A clear nomenclature with respect to the different degrees of N-deacetylation between 
chitin and chitosan has not been defined and as such chitosan is not one chemical entity but 
varies in composition depending on the manufacturer. In essence, chitosan is chitin 
sufficiently deacetylated to form soluble amine salts. The degree of deacetylation necessary 
to obtain a soluble product must be greater than 80–85%.  
Chitosan is commercially available in several types and grades that vary in molecular 
weight by 10000–1000000, and vary in degree of deacetylation and viscosity. 
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Structural Formula 
  
                            Structure of chitosan 
Functional category  
Coating agent; disintegrant; film forming agent; mucoadhesive; tablet binder; 
viscosity increasing agent.   
Description  
Chitosan occurs as odorless, white or creamy white powder or flakes. Fiber formation 
is quite common during precipitation and the chitosan may look ‘cottonlike’.  
 Typical properties  
Chitosan is a cationic polyamine with a high charge density at pH <6.5; and so 
adheres to negatively charged surfaces and chelates metal ions. It is a linear polyelectrolyte 
with reactive hydroxyl and amino groups (available for chemical reaction and salt formation). 
The properties of chitosan relate to its polyelectrolyte and polymeric carbohydrate character. 
The presence of a number of amino groups allows chitosan to react chemically with anionic 
systems, which results in alteration of physicochemical characteristics of such combinations. 
The nitrogen in chitosan is mostly in the form of primary aliphatic amino groups. Chitosan 
therefore undergoes reactions typical of amines: for example, N-acylation and Schiff 
reactions. Almost all functional properties of chitosan depend on the chain length, charge 
density, and charge distribution. Numerous studies have demonstrated that the salt form, 
molecular weight, and degree of deacetylation as well as pH at which the chitosan is used all 
influence how this polymer is utilized in pharmaceutical applications.  
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Table.7: Properties of Chitosan 
PARAMETERS DESCRIPTION 
Appearance (powder or flake) White or yellow 
Particle size Less than 30 μm 
Viscosity (1% solution/ 1% acid) Less than 5 cps 
Density Between 1.35 to 1.40 g/cm
3
 
Molecular weight 50,000 to 2,00,000 Da. 
pH 6.5 to 7.5 
Moisture content More than 10% 
Ash value More than 2% 
Mater insoluble in water 0.5% 
Degree of acetylation 66%  to 99.8% 
Heavy metal (Pb) Less than 10 ppm 
Heavy metal (As) Less than 10 ppm 
Protein content Less than  0.3% 
Loss on drying Less than  10% 
Glass transition temperature 203
o
C 
 
Moisture content 
Chitosan adsorbs moisture from the atmosphere, the amount of water adsorbed 
depending upon the initial moisture content and the temperature and relative humidity of the 
surrounding air.  
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Solubility 
Sparingly soluble in water; practically insoluble in ethanol (95%), other organic 
solvents, and neutral or alkali solutions at pH above approximately 6.5. Chitosan dissolves 
readily in dilute and concentrated solutions of most organic acids and to some extent in 
mineral inorganic acids (except phosphoric and sulphuric acids).  
Viscosity (dynamic) 
A wide range of viscosity types is commercially available. Owing to its high 
molecular weight and linear, unbranched structure, chitosan is an excellent viscosity 
enhancing agent in an acidic environment. It acts as a pseudo plastic material, exhibiting a 
decrease in viscosity with increasing rates of shear. The viscosity of chitosan solutions 
increases with increasing chitosan concentration, decreasing temperature, and increasing 
degree of deacetylation.  
Stability and Storage Conditions  
Chitosan powder is a stable material at room temperature, although it is hygroscopic 
after drying. Chitosan should be stored in a tightly closed container in a cool, dry 
place.Chitosan should be stored at a temperature of 2–8oC. 
Preparation of Chitosan (CS) from Raw Materials 
CS is not a single chemical entity, but varies in composition depending on the source 
and method of preparation defined as sufficiently deacetylation of chitin to form a soluble 
amine salts. The degree of deacetylation must be 80 to 85% or higher or the acetyl content 
must be less than 4-4.5% to form the soluble product. CS is manufactured commercially by a 
chemical method. Firstly the sources such as crab or shrimp shells are washed and grinded in 
to powdered form and then it is deproteinized by treatment with an aqueous 3-5% solution of 
sodium hydroxide. After that it is neutralized and demineralized at a room temperature by 
treating it with aqueous 3-5% of hydrochloric solution to form a white or slightly pink 
precipitate of chitin. Then chitin is deacetylated by treatment with an aqueous 40-45% of 
sodium hydroxide solution and the precipitate is then washed with water. The insoluble part 
is removed by dissolving in an aqueous 2% acetic acids solution. The supernatant solution is 
then neutralized with an aqueous sodium hydroxide solution to obtain a purified CS 
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Incompatibilities  
 Chitosan is incompatible with strong oxidizing agents.  
 Safety  
Chitosan is being investigated widely for use as an excipient in oral and other 
pharmaceutical formulations. It is also used in cosmetics. Chitosan is generally regarded as a 
nontoxic and nonirritant material. It is biocompatible with both healthy and infected 
skin.Chitosan has been shown to be biodegradable. 
LD50 (mouse, oral) >16 g /kg. 
Applications in Pharmaceutical Formulation: 
Chitosan is used in cosmetics and is under investigation for use in a number of 
pharmaceutical formulations. The suitability and performance of chitosan as a component of 
pharmaceutical formulations for drug delivery applications has been investigated in numerous 
studies. These include controlled drug delivery applications 
 Component of mucoadhesive dosage forms 
 Rapid release dosage forms 
 Improved peptide delivery 
 Colonic drug delivery systems 
 Use for drug & gene delivery 
Chitosan has been processed into several pharmaceutical forms including gels, films, 
beads, microspheres, tablets and coating for liposomes. Furthermore, chitosan may be 
processed into drug delivery systems using several techniques including spray-drying, 
coacervation, direct compression and conventional granulation process. 
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8. MATERIALS & METHODS 
List of chemicals used 
Table.8: List of chemicals 
S.No Name of the material Manufacturer Use in 
formulation 
1. Simvastatin Orchid chemicals, 
Chennai. 
Active ingredient 
2. Chitosan Lab Chemicals, Chennai. Polymer 
3. Acetic acid Alan Medicals & Laboratory 
products, 
Chennai. 
Solvent 
4. Acetone RFCL Limited, New Delhi. Solvent 
5. Cholesterol Micro Fine Chemicals, Chennai. Fatty diet 
6. Sodium Cholate Kemwell pharmaceuticals, 
Bangalore. 
Fatty diet 
7. Coconut oil Home made. Fatty diet 
8. Carboxy methyl cellulose Chenchems, Chennai. Suspending agent 
9. Acetic anhydride Medical supplies, England. Reagent 
10. Sulphuric Acid Paxmy speciality chemicals, 
Chennai. 
Reagent 
11. Sodium tungstate LC Industrials, Mumbai. Reagent 
12. Phosphoric acid Chenchems, Chennai. Reagent 
13. Calcium chloride Indian Research Products, 
Chennai. 
Reagent 
14. Ether TKM pharma, Hydrabad. General 
anaesthesia 
15. Potassium dihydrogen  
Phosphate 
Merck specialities Pvt.Ltd, 
Mumbai. 
Buffer 
16. Sodium hydroxide Indian Research Products, 
Chennai. 
Buffer 
17. Methanol Supra chemicals, Chennai. Solvent 
18. Glycerin Microfine chemicals, Chennai. Humectant 
19. Potassium bromide Merck, Germany. Medium 
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List of instruments/ equipment’s used 
Table.9: List of instruments 
S.No Equipments/Instruments Manufacturer 
1. Electronic weighing balance Shimadzu, Japan. 
2. Magnetic stirrer Remi. 
3. Hot Air Oven Industrial heaters, Chennai. 
4. High speed homogenizer Remi, Vasai. 
5. Cooling centrifuge Remi, Vasai. 
6. Lyophilizer Remi, Vasai. 
7. UV- Visible Spectrophotometer Shimadzu, Japan. 
8. Fourier Transform Infrared Spectrophotometer Nicolet, India. 
9. Olympus Binocular Microscope Remi. 
10.  pH meter Symchrony. India. 
11. Ultrasonic cell crusher Lark. 
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9. FORMULATION DEVELOPMENT 
PREFORMULATION STUDIES
78
 
The pre-formulation studies are the first step in the rational development of any 
formulation. It can be defined as the “investigation of physical and chemical properties of the 
drug substance alone and combined with excipients”. These studies focus on those 
physicochemical properties of new compound that could affect drug performance and 
development of an efficacious formulation. The overall objective of preformulation testing is 
to generate information useful to the formulator in developing stable and bioavailable dosage 
forms that can be mass produced. The type of information needed will depend on the dosage 
form to be developed.  
 
Thus the goals of the final study are, 
1. To establish physical characteristics  
2. To establish its compatibility with the excipient  
3. To determine kinetic rate profile  
 
Calibration Curve of Simvastatin in 6.8pH Phosphate Buffer
79
 
Preparation of 6.8pH Phosphate buffer 
 0.2M solution of potassium dihydrogen phosphate was prepared by dissolving 
27.218gm of substance in 1000ml of distilled water. 
 0.2M solution of sodium hydroxide solution was prepared by dissolving 8gm of 
substance in 1000ml of distilled water. 
 50ml of above prepared potassium dihydrogen phosphate solution & 22.4ml of 
sodium hydroxide solution were mixed together and made upto 2000ml and the pH 
was adjusted to 6.8. 
DETERMINATION OF λ max46 
A stock solution of 1 mg/ml of Simvastatin was prepared by dissolving 100 mg of 
drug in small quantity of ethanol and sonicated for few minutes. The solution was diluted 
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with 100 ml of phosphate buffer (pH 6.8) and serially diluted to get solution in the range of 
20µg/ml. The λ max of the solution was found out by scanning from 200 - 400 nm. The λmax 
of Simvastatin was used for further quantitative analysis. 
CALIBRATION CURVE  
A stock solution of 1 mg/ml of Simvastatin was prepared by dissolving 100 mg of 
drug in small quantity of methanol and sonicated for few minutes. It was diluted to 100ml 
with phosphate buffer (pH 6.8). The stock solution was serially diluted to get solutions in the 
range of 2-10µg/ml. The absorbance of the different diluted solutions was measured in a UV-
Visible spectrophotometer at 238 nm. A calibration curve was plotted taking concentration of 
solution in X axis and absorbance in Y axis and correlation coefficient „r‟ was calculated. 
Polymer compatibility studies
48
 
The proper design and formulation of a dosage form requires consideration for 
physical, chemical and biological characteristics of all drug substances and excipients used in 
fabricating the final product. The successful formulation of a stable and effective formulation 
depends on the selection of excipients. The drug and the excipient must be compatible with 
one another to produce a stable product efficacious and easy to administer. 
Fourier Transformation Infrared Spectroscopy: 
Compatibility study was studied by recording the sample using Perkin Elmer Fourier 
transformation Infrared spectroscope (FT-IR) combined to PC (with spectrum 2000 analysis 
software) in the range of 4000 cm
-1
 to 400 cm
-1
. Potassium Bromide Press Pellet was 
prepared by applying pressure of 5 tons for 5 min in a hydraulic press. The pellet was placed 
in light path and the spectra were analysed. 
Composition for FT-IR Study -Table.10 
S.NO INGREDIENTS 
1. Chitosan 
2. Simvastatin 
3. Chitosan and Simvastatin admixture 
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Preparation of chitosan nanoparticles
66
 
Nanoparticles are prepared by Nano precipitation -solvent deposition method using 
chitosan as a coating material and Simvastatin as a core material. Drug and polymer in 
different ratios were weighed and dissolved in a suitable organic solvents, Acetone & 1.5% 
Acetic acid respectively. Both solutions were mixed and added drop wise into water, mixed at 
3000 rpm for 2 hrs forming a milky colloidal suspension and homogenised at 25000 rpm. The 
resultant nanoparticle suspension was recovered by centrifugation (REMI cooling centrifuge) 
at 12000 rpm for 30 min and lyophilized. 
Table.11: Formulation Table 
S.No Formulation Amount of 
drug (mg) 
Concentration of 
Chitosan (%) 
Acetone 
(ml) 
Acetic 
acid (ml) 
Dis.water 
(ml) 
1. F1 50 0.1 5 50 60 
2. F2 50 0.2 5 50 60 
3. F3 50 0.3 5 50 60 
4. F4 50 0.4 5 50 60 
 
Characterization: 
Percentage yield
80
 
The nanoparticle yield was calculated according to the equation given below. 
             Mass of nanoparticles 
Process Yield (%) = ------------------------------------ X 100 
                                 Total mass of drug + polymer  
 
Loading efficiency & Entrapment efficiency
66
 
The Nanosuspension with known amount of drug was centrifuged at 5000 rpm for 15 
minutes. The supernatant solution was separated. 5ml of supernatant was distributed with 
50ml of phosphate buffer solution pH 6.8 and the absorbance was measured using UV 
spectrophotometer at 238 nm using phosphate buffer solution pH 6.8 as blank. The amount of 
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drug unentrapped was calculated. The percentage of entrapment and loading efficiency was 
determined according to the equation given below.  
Loading efficiency (%, w/w) =  Total amount of drug - Amount of unbound drug 
                                                   ------------------------------------------------------------- X 100 
                                                              Nanoparticles weight  
  
Drug entrapment (%, w/w) = Mass of the total drug −Mass of free drug  
                --------------------------------------------------- X 100 
                                                             Mass of total drug 
DETERMINATION OF DRUG CONTENT
46
 
Equivalent to 1mg of the prepared formulations were weighed and dissolved in 
minimum quantity of Ethanol and made up to 50ml with phosphate buffer (6.8pH). The 
absorbance of the solutions was measured at 238nm. The drug content was calculated. 
Optimization of formulation 
Photon Correlation Spectroscopy (PCS) 
45
 
 
The particle size of the resulting nanoparticles was determined by PCS. A BI-200SM 
Goniometer Version 2.0 (Marlvern Instruments, Germany). The particle size was expressed by 
the effective diameter and the width of size distribution was characterized by polydispersity 
index. The particle size, their range and degree of distribution were studied for the best 
formulation.  
Zeta Potential Measurements
81, 82
 
Zeta potential measurements are generally performed to determine the stability of the 
nanoparticles. 
Three of the fundamental states of matter are solids, liquids and gases. If one of these 
states is finely dispersed in another then it is known as “colloidal system”. In certain 
circumstances, the particles in a dispersion may adhere to one another and form aggregates of 
successively increasing in size, which may settle out under the influence of gravity. 
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Zeta potential is a physical property which is exhibited by any particle in a colloid, 
suspension or emulsion. It can be used to optimize the formulations. Knowledge of the zeta 
potential can reduce the number of trials in formulations. It is also useful in predicting long-
term stability. 
The particles in a colloidal suspension usually carry an electrical charge. The charge 
is more often negative than positive. Sometimes the surface of the particles which is 
containing chemical groups can ionize to produce a charged surface. Sometimes the surface 
itself preferentially adsorbs ions of one sign of charge in preference to charges of the opposite 
sign. In other cases there may be deliberately added chemical compounds that preferentially 
adsorb on the particle surface to generate the charge. 
However it may happen, the amount of charge on the particle surface is an important 
particle characteristic because it determines many of the properties of the colloids. 
a) Zeta Potential Range 
The zeta potential is the overall charge a particle acquires in a specific medium. 
 The magnitude of the zeta potential gives an indication of the potential stability of the 
colloidal system. 
 If all the particles have a large negative or positive zeta potential they will repel each 
other and there is dispersion stability. 
 If the particles have low zeta potential values then there is no force to prevent the 
particles coming together and there is dispersion instability. 
 A dividing line between stable and unstable aqueous dispersions is generally taken at 
either +30 or -30mV. 
 Particles with zeta potentials more positive than +30mV are normally considered 
stable. 
 Particles with zeta potentials more negative than -30mV are normally considered 
stable. 
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Fig.14: Zeta potential 
Procedure: 
Zeta potential is done using water as a dispersant which has refractive index 1.330, 
viscosity 0.8872 and dielectric constant 78.5 at 25˚C. 
Scanning electron microscopic (SEM) 
SEM photographs were taken with a scanning electron microscope [Model Vega3-
Tescan, USA] at the required magnification at room temperature. The Nanoparticles, pure 
Simvastatin were deposited on a glass disc applied on a metallic stub separatly and 
evaporated under a vacuum overnight. Before the SEM analysis, the samples were metallized 
under an argon atmosphere with a 10-nm gold palladium (EMITECH- K550 Sputter Coater, 
Houston, TX). 
DIFFERENTIAL SCANNING COLORIMETRY (DSC) 
Differential scanning colorimetry (DSC) was conducted on Diamond DSC 
Calorimeter at Anna University. The samples were equilibrated at 20° C for half hour and 
then heated to 220° C at 10° C/ml in a N2 atmosphere. 
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FTIR of formulation F3: 
  
The compatibility study was carried out for the best formulation using Perkin Elmer FTIR 
at wavelength range of 4000 to 400 cm-1 to confirm any interaction between the drug and 
polymer. 
X-RAY DIFFRACTION STUDY 
X-ray diffraction analysis was employed to detect the crystallinity of the pure drug 
and the formulations, which was conducted using a XRD-6000 diffractometer (Shimadzu, 
Japan) at Anna University. The powder was placed in a glass sample holder. CuK radiation 
was generated at 30mA and 40 kV. Samples were scanned from 5° to 50° with a step size of 
0.02° and the scan speed was 3° min
-1 
 
In-vitro drug release characteristics
83
 
The in-vitro drug diffusion from the formulation was studied using cellophane 
membrane. Phosphate buffer pH 6.8 was used as a dissolution medium solution. Cellophane 
membrane was previously soaked in the mixture of glycerol & water (1:4 ratio) for 20minutes 
and the cellophane membrane was tied to one end of a specially designed glass cylinder 
(open at both ends). 10 ml of formulation was accurately placed into this assembly. The 
cylinder was suspended in 200 ml of dissolution medium maintained at 37 ± 5ºC. The 
dissolution medium was stirred at 100 rpm using magnetic stirrer. 10 ml samples were 
withdrawn at hourly intervals and replaced by an equal volume of receptor medium. The 
aliquots were analyzed by UV-Vis Spectrophotometer at 238 nm. The cumulative % release 
of the formulations was calculated. 
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PHARMACOKINETICS 
In-vitro release kinetics (theoretical calculation from % Cumulative drug release). 
To study the release kinetics, data obtained from in-vitro release were fitted in various 
kinetic models. 
a) Zero order reaction: 
A graph was plotted with % drug released vs. time. 
C=K0t 
 Where K0  - Zero order rate constant  
           t   - time 
           C- % drug released 
b) First order reaction: 
A graph was plotted with log cumulative % drug remaining vs. time. 
Log C=log C0-Kt /2.303 
Where C0 - Initial concentration of drug. 
             K-First order constant, t - time. 
c) Higuchi kinetics: 
A graph was plotted with cumulative % drug released vs. square root of time 
Q=Kt½ 
Where K - constant reflecting design variable of system. (Differential rate constant) 
           t  - time. 
The drug release rate is inversely proportional to the reciprocal of square root of time. 
If the plot yields a straight line, and the slope is one, then the particular dosage form is 
considered to follow Higuchi kinetics of drug release. 
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d) Hixson Crowell erosion equation: 
To evaluate the drug release with changes in the surface area and the diameter of 
particles, the data were plotted using the Hixson Crowell equation. A graph was plotted with 
cube root of % drug remaining vs. time in days. 
Q0
1/3 –Qt
1/3
 =KHC X t 
 Where Qt -  Amount of drug released in time t. 
           Q0 -  Initial amount of drug 
       KHC - Rate constant for Hixson Crowell equation. 
e) Korsmeyer –Peppas equation: 
To evaluate the mechanism of drug release, the drug release was fitted in Peppas 
equation with log cumulative of drug released vs. time. 
Mt/Mα= Ktn 
   Log Mt/ Mα= log K+ n log t 
Where Mt/Mα –fraction of drug released at time t 
             K - kinetic constant (incorporating structural and geometric characteristics of 
preparation) 
            n- diffusional exponent indicative of the mechanism drug release. 
If n value is 0.5 or less, the release mechanism follows “Fickian diffusion”. 0.5 to 1 it 
follows a non-fickian model (anomalous transport).The drug release follows zero-order drug 
release and case II transport if the n value is 1. For the values of n higher than 1, the 
mechanism of drug release is regarded as super case II transport. This model is used to 
analyse the release of pharmaceutical polymeric dosage forms when the release mechanism is 
not known or more than one type of release phenomenon is involved. The n value could be 
obtained from slope of the plot of log cumulative % of drug released vs. log time. 
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Stability studies 
Stability of Simvastatin nanoparticles was carried out at room temperature, 
refrigeration and accelerated condition at 40
0
C/75% RH for a period of 3 months. Then the 
samples were analyzed spectrophotometrically. 
In-vivo Study
51
 
Selection of animal species  
The albino rats (Wistar strain) of either sex having weight 150 to 250 g were used for 
testing antilipidemic activity. 
Experimental animals 
Animals had free access to food and water ad libitum. The effect of optimized 
formulation (test formulation) on plasma lipid profiles was determined and compared with 
reference formulation (aqueous suspension containing Simvastatin equivalent to 10 mg/ kg 
and carboxy methyl cellulose 0.25% w/v as a suspending agent) in healthy albino rats. The 
animals were randomly divided into 4 treatment groups of six animals each, viz., Control 
Treatment Group (CTG), Hyperlipidemic Treatment Group (HTG), Reference Treatment 
Group (RTG) and Test Treatment Group (TTG). The treatment was given for 21 days. Each 
treatment group received daily standard cholesterol diet (2% coconut oil, 2% cholesterol and 
1% sodium cholate) orally in the morning throughout 21 days to induce hyperlipidemia 
except control treatment group. High cholesterol diet was prepared by mixing cholesterol 2%, 
sodium cholate 1% ,and coconut oil 2% with standard powdered animal food. The diet was 
placed in the cage carefully for 21 days for hyperlipidemic control group, reference treatment 
group and test treatment groups. 
Collection of Blood samples 
Blood samples were collected under light ether anaesthesia by retro-orbital puncture 
at predetermined time intervals, viz., before treatment, and after 0, 5, 10, 15, 21 days in 
centrifuge tube. Plasma was separated by centrifugation at 3000 rpm for 25 min and stored 
frozen until further use. 
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Biochemical analysis 
The lipid profiles -Total Cholesterol (CH), triglycerides (TG), low density 
lipoproteins (LDL-C),very low density lipoproteins(VLDL) and high density lipoproteins 
(HDL-C) levels) were estimated to confirm the induction of hyperlipidemia. LDL-C and AI, 
in plasma was calculated as per Friedewald estimation. Fixed volumes of sample and 
standard were mixed with the working reagent and incubated at 37°C for 10 min. The 
absorbance of the developed colour was read at 505 nm for CH and at 546 nm for TG. 
ESTIMATION OF CHOLESTEROL
84
 
A single stable Liebermann-Burchard reagent was prepared and used for the rapid and 
accurate determination of total cholesterol in serum. 
Preparation of Libermann-Burchard reagent 
In the preparation of the Liebermann-Burchard (LB) reagent, the following reagents 
are necessary: (1) glacial acetic acid, AR; (2) acetic anhydride, AR; (3) sulfuric acid, AR. It is 
very important that all glassware for the preparation of this reagent be chemically clean and 
dry. 
 Acetic anhydride and concentrated sulfuric acid were cooled in ice water. 24 ml of 
cold Acetic anhydride and 22 ml of Glacial Acetic acid (room temperature) were added to an 
amber coloured glass bottle. It was mixed by inversion, 4 ml of cold concentrated sulfuric 
acid, the reagent was added and mixed. 
It is stable for more than 6 months when stored at 4
0
c in the dark. When stored at 
room temperature, the reagent shows signs (darkening) of deterioration after 1-2 weeks. 
Standard Curve 
 A 200 mg/100 ml cholesterol standard was prepared by dissolving 100 mg cholesterol in 50 
ml glacial acetic acid and stored in an amber glass bottle. 
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Procedure 
 The test tubes were labelled as „C‟, „H‟, „R‟, „T‟, „S‟ and „B‟. 6ml of LB reagent was 
pipetted. 
 To the „C‟, „H‟, „R‟ and „T‟ test tubes, 0.2ml of unknown serum from respective 
groups of animals was added. To the „S‟ test tube, 0.2ml of cholesterol standard was 
added and mixed with the aid of vortex mixer. 
 All the test tubes were incubated at 370c for 18 minutes. 
 The tubes were wiped and the absorbance was measured at 505 nm at regular timed 
intervals over the next 10 minutes, using LB reagent as blank. 
 Using the standard photometric formula, the concentration of the unknown is 
calculated. 
         
Cu = Cs X (Au/As) 
Where, Cu, Cs - Concentration of unknown and standard respectively. 
 Au,  As - Absorbance of unknown and standard respectively. 
 
ESTIMATION OF TRIGLYCERIDES USING COLORIMETRY
85
 
Sample preparation 
  The blood was collected without using an anticoagulant 
  It was allowed to clot for 30 minutes at 25oC 
 The blood was centrifuged at 2000rpm for 15minutes at 40C. The top yellow serum 
layer was pipetted out without disturbing the white buffy layer. The serum was stored 
on ice and assayed. 
 Calculate the values of triglyceride samples using the equation obtained from the 
linear regression of the standard curve by substituting the corrected absorbance values 
for each sample into the equation 
        Corrected absorbance – (y-intercept) 
Triglycerides (mg/dl) =  ---------------------------------------------- 
              Slope 
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ESTIMATION OF HDL BY PTA (PHOSPHO TUNGSTIC ACID) METHOD
86
 
PROCEDURE 
 The tube was labelled for reagent blank, standard and unknown sample (test). 
 1.0 ml of reagent was added to each tube and brought to assay temperature (25°, 30° 
or 37°C). 
 0.05ml of water was added to the reagent blank. 0.05ml of standard and sample was 
added to the appropriate tube, mixed and incubated at 37°C for 6 minutes  
 The absorbance was measured. 
 The concentration of unknown were calculated using the following formula 
 
Cu = Cs X (Au/As) 
Atherogenic index, VLDL and VLDL was calculated using the following formula 
ATHEROGENIC INDEX
87
 
   AI = log (TG/HDL) 
LOW DENSITY LIPOPROTEINS 
   LDL = TC- HDL-(TG/5) 
VERY LOW DENSITY LIPOPROTEINS 
   VLDL = TG/5 
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10. RESULTS AND DISCUSSION 
Pre-formulation Studies:  
The optimization of a formulation can be done only after a thorough investigation of 
its physicochemical properties of the drug and excipient. The drug and the polymer must be 
compatible for a successful formulation.  
UV-visible spectroscopy and FTIR spectroscopy gives the possible information about 
the interaction between the drug and polymer. 
 Values for standard curve of Simvastatin at 238nm. 
Table.12: Absorbance of Simvastatin 
S.No Concentration 
µg/ml 
Absorbance 
1. 2 0.131 
2. 4 0.264 
3. 6 0.393 
4. 8 0.524 
5. 10 0.645 
 
Inference:  
The ultraviolet spectrophotometric method was used to analyze Simvastatin at 
wavelength of 238nm. Absorbance of the Simvastatin shown in Table.12. The standard plot 
was prepared in phosphate buffer 6.8. It showed linearity at concentration range of 2 to 10 
μg/ml shown in Fig.15. 
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Fig.15: Simvastatin Calibration curve 
Drug – polymer compatibility studies:  
The physical state of Simvastatin, Chitosan and physical admixture of the Chitosan & 
Simvastatin were subjected to FTIR spectroscopy. 
FTIR studies: 
Comparison of IR peaks of polymer and drug admixtures. 
Table.13: FTIR peaks 
S.No Samples Wave number(cm
-1
) 
1. Chitosan 3394, 2923, 2885, 1650, 1589, 1419, 1380, 
1319, 1072. 
2. Simvastatin 3548, 3417,2962,2877,1836, 1704, 1458, 
1388, 1265, 1064. 
3. Chitosan & Simvastatin 3749, 3548, 3417, 2954,2877,1828,1704, 
1458,1388,1265,1064. 
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FTIR of Simvastatin 
 
Fig.16: FTIR of Simvastatin 
FTIR of Chitosan- Fig.17 
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FTIR data of Simvastatin and Chitosan 
 
Fig.18: FTIR of Simvastatin and Chitosan 
Inference 
 The IR spectra are shown in the figures16, 17 and 18. No change in peaks of 
admixture compared with drug indicates the absence of any interaction. 
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FTIR data of simvastatin- Table.14 
S.No Functional group Standard wave 
number 
Peak observed in 
Simvastatin API (cm
-1)
 
1. Free O-H stretch 3546 3548 
2. Methyl C-H symmetric stretch; 
Methylene C-H asymmetric 
stretch 
2924 2962 
3. Ester C =O stretch 1697 1704 
4. Methylene C-H symmetric bend, 
Methyl C-H symmetric bend 
1461 1458 
5. Lactone-C-O-C bend 1268 1265 
6. Ester-C-O-C-bend 1164 1164 
7. Secondary alcohol C-O stretch 1072 1064 
8. N-H stretching 1568 1836 
 
FT-IR data of chitosan- Table.15 
S.No. Functional group Peak observed in chitosan (cm-1) 
1. N-H symmetric stretching vibration 3450 
2. OH stretching 3394 
3. C-H stretching vibration 2923 
4. NH bending (amide II) (NH2) 1560,1639 ,1319 
5. C=0 stretching (amide I) 0=C-NHR. 1647 
6. CH2 bending 2927, 2885, 1419, 1319, 1265 
7. CH3 wagging 1380 and 1319 
8. >CO-CH3 stretching vibration 1072 
9. Confirmed a saccharide structure 1265, 1157 
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FTIR data of simvastatin and Chitosan- Table.16 
Interpretation Wave number(cm
-1
) 
N-H symmetric stretching vibration 3749 
Free OH stretch 3548 
N-H symmetric stretching vibration 3417 
Methyl C-H symmetric stretch; 
Methylene C-H asymmetric stretch 
2954 
CH2 bending 2877 
N-H stretching 1828 
Ester C =O stretch 1704 
Methylene C-H symmetric bend, 
Methyl C-H symmetric bend 
1458 
CH3 wagging 1388 
CH2 bending 1265 
>CO-CH3 stretching vibration 1064 
 
Inference:  
 The interpretation of IR spectra shown in Table no.14, 15 and 16. No interaction was 
observed between Simvastatin and Chitosan. They are compatible. 
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Formulation: 
 Simvastatin nanoparticles were prepared by Nanoprecipitation method using chitosan 
as a polymer with various ratios of drug and polymer. Formed Nanoparticles were separated 
by centrifugation. 
Simvastatin loaded Chitosan nanoparticles 
 
Fig.19: Simvastatin nanoparticles 
CHARACTERISATION 
Table.17 
S.No Formulation Entrapment 
efficiency 
(%) 
Percentage 
yield (%) 
Loading 
efficiency 
Drug 
content 
1. F1 89.15 25.16 16.3 32.68 
2. F2 95.56 44 14.8 44.40 
3. F3 97.43 52 17.07 68.32 
4. F4 93.85 32.9 6.02 30.12 
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ENTRAPMENT EFFICIENCY 
 
Fig.20: Entrapment efficiency 
Inference 
 High chitosan concentration (4mg/ml) resulted in lesser encapsulation. Low chitosan 
concentration (1mg/ml) resulted in aggregates. The formation of nanoparticle was only 
possible within moderate concentration of chitosan. Chitosan solution within the 
concentration of (3mg/ml) produced opalescent nanoparticle suspension. Further increase in 
Chitosan concentration lead to decrease in encapsulation efficiency of Simvastatin 
nanoparticles. Chitosan concentration (such as 3mg/ml) promote the encapsulation of the 
drug.  
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PERCENTAGE YIELD 
 
Fig.21: Percentage yield 
Inference 
  1:3 ratio showed better yield shown in Fig.21 compared to other three ratios. 
Increased drug entrapment causes increased yield. It was assumed that the high entrapment of 
Simvastatin was due to its poor aqueous solubility, high binding of drug & polymer in 
organic phase and increased polymer ratio. 
LOADING EFFICIENCY 
 
Fig.22: Loading efficiency 
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Inference 
 Formulation F3 showed highest dug loading capacity due to increasing polymer 
concentration. 
DRUG CONTENT 
 
Fig.23: Drug content 
Inference 
  The particle size of the nanoparticles was increased by increasing drug polymer ratio. 
Due to increased particle size, the drug content also increased from 32.68% to 68.32% as on 
increasing drug/polymer ratio from 1:1 to 1:3. There was no significant increase in drug 
content as polymer concentration was increased. This was probably caused by the increasing 
viscosity and hence poor dispersibility of Chitosan solution into the aqueous phase. 
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Particle size and Zeta potential of nanoparticles 
Table.18: Particle size and Zeta potential 
S.No Batch.code Polydispersity index Average size 
(nm) 
Zeta potential 
(mv) 
1 F1 0.324±0.017 200±1.18 +16.3±1.6 
2 F2 0.286±0.02 257±2.27 +17.6±1.8 
3 F3 0.241±0.016 398±1.13 +19.8±2.2 
4 F4 0.232±0.012 360±1.24 +20.5±1.6 
 
Inference  
Particle size is usually used to characterize the nanoparticles, because it facilitates 
understanding of dispersion and aggregation. Larger surface area and attractive forces 
between particles accompanies more aggregation of particles. The result showed that the 
average size of prepared nanoparticles varies from 200±1.18 to 398±1.13 shown in Table.18 
with a polydispersity index in the range of 0.232+0.012 to 0.364+0.013. As the amount of 
polymer increased, size of the nanoparticles also increased. It was reported that polydispersity 
index more than 0.5 is indicative to aggregation of particles.  
Zeta potential of prepared nanoparticles was found to range between +16.3±1.6 to 
+20.5±1.6mV. It was found that higher the zeta potential, less will be the particle 
aggregation, due to electric repulsion and hence more will be the stability of nanoparticles. It 
was observed that positive charge appear on nanoparticles surface which is attributed to the 
presence of the quaternary ammonium groups of chitosan. 
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SEM image of pure Simvastatin
 
Fig.24: SEM image of Simvastatin 
SEM image of Simvastatin nanoparticle- Fig.25: SEM image of Simvastatin Nano 
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Inference 
The prepared nanoparticles were spherical in shape with a smooth surface. Particle 
size of prepared nanoparticles was found to be in the range of 360nm to 480nm shown in 
Fig.25. Pure simvastatin used for the study was characterized by relatively large particles 
with average value of about 28.3 µm as reported sown in Fig.24. The nanoparticles showed a 
drastic decrease in the particle size when compared to the pure drug particles. As per Noyes-
Whitney equation, the decrease in the particle size will have a positive effect on the drug 
dissolution rate. Hence this decrease in the particle size achieved will have a significant effect 
in the drug solubility and dissolution characteristics. 
 
Differential Scanning Colorimetry 
 
 Fig.26: DSC Thermogram of pure drug (Simvastatin) 
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Fig.27: DSC Thermogram of Simvastatin Nanoparticles 
 
Inference 
 The DSC curves of commercial simvastatin showed a broad endotherm ranging from 
30 to 120°C indicating the loss of water and the sharp endotherm at 138.97°C might be due to 
the melting point of simvastatin shown in Fig.26, 27. There was no significant change in the 
melting points of the Formulation F3. Hence it is inferred that the drug and the polymer is 
compatible with each other. 
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FTIR of Simvastatin nanoparticle 
 
Fig.27: FTIR of Simvastatin Nanoparticle 
FTIR data of Simvastatin nanoparticle- Table.19 
Interpretation Wave number(cm
-1)
 
N-H symmetric stretching vibration 3741 
N-H symmetric stretching vibration 3695 
Free OH stretch 3548 
N-H symmetric stretching vibration 3425 
Methylene C-H asymmetric stretch 2954 
CH2 bending 2877 
Ester C =O stretch 1704 
Methyl C-H symmetric bend 1458 
CH3 wagging  1388 
CH2 bending 1265 
Lactone-C-O-C bend 1226 
Confirmed a saccharide structure 1164 
Secondary alcohol C-O stretch 1118 
>CO-CH3 stretching vibration 1064 
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Inference 
It was evident that all the characteristic peaks of Chitosan and Simvastatin were also 
in the formulation F3. Hence it was concluded that the drugs were compatible with the 
polymer, shown in Fig.27 and Table.19. 
X-RAY DIFFRACTION STUDY 
 
Fig.28: XRD Pattern of Pure Drug (Simvastatin) 
 
Fig.29: XRD Pattern of Simvastatin Nanoparticles 
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Inference 
 XRD pattern of the pure drug and selected formulation are showed Characteristic 
diffraction peaks were observed for commercial simvastatin. On the other hand, the nano 
formulations particles prepared with Chitosan was characterized by less intensity of the 
diffraction peak when compared to that of simvastatin. This clearly indicates the reduction in 
the crystallanity of the precipitated simvastatin nanoparticles shown in Fig. 28 and 29. 
 
In-vitro drug release 
Table.20: In-vitro drug release* 
Time(Hours) Control F1 F2 F3 F4 
1 45.45±1.20 46.53±1.02 25.22±0.23 19.71±1.05 10.97±0.61 
2 52.60±0.10 51.67±0.26 28.08±1.03 24.28±1.24 13±0.42 
3 67.58±1.02 59.96±1.32 29.98±1.25 28.50±1.15 15.58±0.20 
4 79.33±0.25 75.79±1.02 32.98±0.12 38.56±1.10 17.80±0.81 
5 87.80±0.10 82.24±0.29 35.88±0.19 47.27±0.12 19.94±1.22 
6 95.26±0.78 90.90±0.23 38.15±0.15 55.26±0.29 22.07±1.34 
7  96.09±1.28 40.30±1.14 65.90±1.16 24.72±1.82 
8   42.85±1.28 76.94±1.16 26.53±1.13 
9   46.14±1.56 84.79±0.73 27.92±1.55 
10   48.80±1.64 87.12±0.20 29.12±1.51 
11   52.13±0.10 91.34±0.45 32.89±1.87 
12   56.78±1.22 95.66±0.98 37.21±1.22 
24   79.88±1.01  43.43±1.13 
*Mean± S.D (n=3) 
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COMPARATIVE INVITRO DRUG RELEASE FOR ALL FORMULATION 
 
Fig.29: Comparative invitro drug release 
  Inference 
 The formulation F3 showed sustained release of drug shown in Table.20 and Fig.29. 
In vitro drug release of the optimized formulation F3 
Table.21: In-vitro drug release of optimised formulation* 
S.No Time(hours) % cumulative drug 
release 
1. 0 0 
2. 1 19.71±0.61 
3 2 24.28±0.42 
4. 3 28.50±0.20 
5. 4 38.56±0.81 
6. 5 47.27±1.22 
7. 6 55.26±1.34 
8. 7 65.90±1.82 
9. 8 76.94±1.13 
10. 9 84.79±1.55 
11. 10 87.12±1.51 
12. 11 91.34±1.28 
 13. 12 95.66±0.73 
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In-vitro drug release of the optimised formulation 
 
Fig.30: In-vitro drug release 
Inference 
The cumulative % drug release of the formulation F3 was found to be 95.66% at the 
end of 12 hours shown in Fig.30.  
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Data for release kinetics 
Table.22: Data for release kinetics 
Time(hours) % cum 
drug 
release 
%cum 
drug 
remaining 
Log % 
cum drug 
remaining 
Square 
root of 
time 
Log 
time 
Log % 
cum 
drug 
release 
Cube root 
of % drug 
remaining 
0 0 100 2 0 -∞ -∞ 4.641 
1 19.71 80.29 1.904 1.00 0 1.294 4.314 
2 24.28 75.72 1.879 1.414 0.301 1.385 4.230 
3 28.50 71.50 1.854 1.732 0.477 1.454 4.150 
4 38.56 61.44 1.788 2.00 0.602 1.586 3.945 
5 47.27 52.73 1.722 2.236 0.698 1.674 3.749 
6 55.26 44.74 1.650 2.449 0.778 1.742 3.550 
7 65.90 34.10 1.532 2.645 0.845 1.818 3.242 
8 76.94 23.06 1.362 2.828 0.903 1.886 2.846 
9 84.79 15.21 1.182 3 0.954 1.928 2.477 
10 87.12 12.88 1.109 3.162 1 1.940 2.344 
11 91.34 8.66 0.937 3.316 1.041 1.960 2.053 
12 95.66 4.34 0.637 3.464 1.079 1.980 1.631 
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Determination of drug release mechanism of optimized formulation F3. 
 
Fig.31: Zero order release kinetics 
 
 
Fig.32: First order release kinetics 
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Fig.32: Higuchi diffusion kinetics 
 
 
 Fig.33: Korsmeyer Peppas equation 
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Fig.34: Hixon crowel cube root plot 
In-vitro release kinetics 
Table.22: Release kinetics 
S.No Release 
kinetics 
X- 
axis 
Y-axis Slope Intercept R
2
 Linear 
equation 
1. Zero order 
equation 
Time 
in 
hours 
Cumulative 
% drug 
release 
7.9546 7.298 0.981 y=7.9546x+
7.298 
R2=0.981 
2. First order 
equation 
Time 
in 
hours 
Log cum % 
drug 
remaining 
-0.1052 2.1357 0.927
6 
y = -0.1052x 
+ 2.1357 
R² = 0.9276 
 
3. Higuchi 
kinetics 
Square 
root of 
time 
Cum % drug 
release 
30.22 0.7386 -12.95 y = 30.22x – 
12.953 
R² = 0.9477 
 
4. Korsmeyer 
Peppas 
equation 
Log 
time 
Log cum % 
drug release 
0.72 1.199 0.961
2 
y = 0.72x + 
1.199 
R² = 0.9612 
 
5. Hixon 
crowel 
cube root 
equation 
Time 
in 
hours 
Cube root % 
drug 
remaining 
-0.2452 4.7923 0.974
7 
y = -0.2452x 
+ 4.7923 
R² = 0.9747 
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Determination of drug release mechanism of optimized nanoparticle 
 The order of release was found to be zero order, in which R2 value was close to 1. So 
the formulation follows zero order kinetics. It also followed Higuchi release model 
 The n value of Korsmeyer peppas equation was found to be greater than 0.5. It was 
concluded that the release follows a non-fickian diffusion. 
 Good correlation coefficient was obtained for the kinetics parameters based on 
Higuchi’s square root equation and it was found that release follows diffusion kinetics 
mechanism. 
Inference 
Drug may be released from nanoparticles by the mechanism of diffusion. It was 
observed that the mechanism governing release of Simvastatin from chitosan based 
nanoparticles is predominantly drug diffusion. 
Stability studies of the optimized Formulation- F3 
Table.23: Stability studies of optimised formulation- F3 
Temperature Amount of drug retained (%) after months 
Initial I II III 
Refrigeration 
(4
0
 ± 1
0
C) 
82.99±1.10 80.78±0.20 77.90±0.95 75.46±1.23 
Room 
Temperature 
82.99±1.50 78.34±1.76 73.88±0.10 70.66±0.56 
40
0
±2
0
C 
RH-70±5% 
82.99±1.45 74.89±1.89 66.67±0.65 61.10±.90 
*Mean± SD (n=3) 
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Inference: 
  Stability studies for Simvastatin nanoparticles were carried out at various 
temperatures – refrigeration (4˚C), normal room temperature (25˚C) and stability chamber 
(40˚C/75% RH). Simvastatin Nanoparticles stored under refrigerated condition showed 
75.46% after 3 months. 
 Simvastatin nanoparticles stored at room temperature the drug retained after 3 months 
was 70.66%. Simvastatin nanoparticles stored at 40
0
±2
0
C/ 70±5% RH was 61.10% after 3 
months shown in Table.23. 
 The formulations were found most stable at refrigeration temperature 
 Good stability was observed at Room Temperature 
 Drug degraded at 400±20C/70±5% RH. 
 
In-vivo Study 
Hypercholesterolemia was induced in rats by feeding a high cholesterol diet. From 
days 0 to 21, four groups of albino rats were administered nanoparticle dispersion (equivalent 
to 10 mg/kg dose). The results were compared with the group of animals treated with 
reference treatment group as well as two control groups, one group serving as normal control, 
while the other group served as cholesterol control. 
WEIGHT OF THE ANIMALS (g) 
Table.24: Weight of the animals (g) 
Groups 0 day 5
th
 day 10
th
 day 15
th
 day 21
st
 day 
CTG 110 115 120 130 150 
HTG 100 120 130 140 160 
RTG 100 105 110 115 130 
TTG 100 100 100 100 110 
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Inference 
After 21 days of treatment with 2% coconut oil, 2% cholesterol and 1% sodium 
cholate per day, the body weight of rats in CTG, HTG, RTG and TTG groups was increased 
(26.66%, 37.50%, 23.07%  and 9.09% respectively). The increase in body weight of rats in 
TTG is very marginal shown Table.24.  
CHOLESTEROL LEVEL (mg/dl) ** 
Table.25: Cholesterol level 
Groups 0 day 5
th
 day 10
th
 days 15
th
 days 21
st
 days 
CTG 61.01±1.08 61.48±0.555 63.46±0.617 67.44±0.574 73.45±0.852 
HTG 61.43±0.554 71.47±0.579 101.41±0.562                          107.85±0.582 127.01±0.674 
RTG 59.42±0.937 63.47±0.884 91.49±0.751 103.61±0.536 114.84±0.875 
TTG 58.46±0.522 60.52±0.947 84.49±0.617 86.53±1.457 98.34±0.596 
 
CTG- Control treatment groups, HTG- Hyperlipidemic control groups, TTG- Test 
treatment groups, RTG- Reference treatment groups, Significant differences p<0.01 
**Mean ±SD (n=6) 
 
Inference 
 
HTG, RTG showed a marked increase in total CH (127.01±0.674mg/dl, 114.84± 
0.875 mg/dl respectively) .TTG showed an increase of 98.34 ± 0.596mg/dl (p < 0.01). 
Particularly, in the case of HTG a significant increase in CH (p < 0.01) shown in Table.25, 
from day zero to 21 of the treatment, indicated the inducement of hypercholesterolemia due 
to administration of (2% coconut oil, 2% cholesterol and 1% sodium cholate). There was a 
significant difference in the tested parameters for CTG and HTG after the 21 day treatment 
on the lipid profiles of experimental animals. 
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TRIGLYCERIDES LEVEL (mg/dl) ** 
Table.26: Triglycerides level 
Groups 0day 5
th
 day 10
th
 day 15
th
 day 21
st
 day 
CTG 23.53±0.595 25.60±0.618 49.44±0.579 53.31±1.058 56.92±0.630 
HTG 24.27±0.542 36.54±0.525 65.21±0.532 99.44±0.807 185.84±1.070 
RTG 22.51±0.957 29.65±0.673 55.38±0.578 81.59±0.571 101.41±1.219 
TTG 22.47±0.899 24.50±0.619 44.39±0.626 62.53±0.817 84.56±0.550 
**Mean ±SD (n=6) 
 
Inference 
 
HTG, RTG showed a marked increase in total TG (185.84±1.070mg/dl, 101.41± 
1.219mg/dl respectively). TTG showed an increase of 84.56±0.550mg/dl (p < 0.01). 
Particularly, in the case of HTG a significant increase in TG (p < 0.01) shown in Table.26 
from day zero to 21 of the treatment was observed. 
 
HIGH DENSITY LIPOPROTEINS (mg/dl) ** 
Table.27: HDL level 
Groups 0day 5
th
 day 10
th
 day 15
th
 day 21
st
 day 
CTG 24.26±0.602 24.49±0.520 25.53±0.526 25.57±0.629 31.37±0.608 
HTG 24.49±0.585 23.56±0.650 21.44±0.691 20.49±0.597 19.41±0.606 
RTG 23.52±0.621 24.39±0.591 25.32±0.754 26.49±0.570 28.80±0.791 
TTG 22.50±0.795 24.31±0.582 26.62±0.598 29.19±0.530 36.29±0.602 
**Mean ±SD (n=6) 
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Inference 
 
HTG showed a marked decrease in total HDL-CH (19.41±0.606mg/dl) contrast to 
increasing HDL-CH for RTG and TTG (28.80±0.791mg/dl, 36.29±0.602mg/dl respectively) 
(p < 0.01) shown in Table.27. Particularly, in the case of HTG a significant decrease in TG (p 
< 0.01), from day zero to 21 of the treatment was observed. 
 
LOW DENSITY LIPOPROTEINS (mg/dl) ** 
Table.28: LDL level 
GROUPS 0day 5
th
 day 10
th
 day 15
th
 day 21
st
 day 
CTG 32.04±1.381 31.87±0.937 28.10±0.954 31.87±1.245 30.69±0.563 
HTG 32.09±0.966 40.60±0.753 66.97±1.137 65.09±2.200 70.49±0.024 
RTG 31.39±1.485 33.12±1.380 55.08±0.737 60.80±1.135 65.76±0.779 
TTG 31.47±0.454 31.25±0.828 48.99±1.292 45.83±1.065 45.13±0.297 
**Mean ±SD (n=6) 
 
VERY LOW DENSITY LIPOPROTEINS (mg/dl) ** 
Table.29: VLDL level 
GROUPS 0 day 5
th
 day 10
th
 day 15
th
 day 21
st
 day 
CTG 4.70±0.119 5.11±0.124 9.86±0.11 9.99±0.729 11.38±0.126 
HTG 4.85±0.108 7.305±0.104 12.99±0.112 19.78±0.206 36.99±0.343 
RTG 4.50±0.192 5.926±0.134 11.07±0.115 16.31±0.11 20.27±0.243 
TTG 4.49±0.178 4.89±0.123 8.87±0.125 12.50±0.164 16.90±0.111 
**Mean ±SD (n=6) 
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Inference 
In TTG, the increase in LDL-CH and VLDL were (45.13±0.297mg/dl, 16.90±0.111, 
respectively). The increase in LDL-CH and VLDL for CTG (30.69±0.563mg/dl, 11.38±0.126 
respectively) p<0.01, shown in Table 28 and 29.  
 
 
ATHEROGENIC INDEX ** 
Table.30: Atherogenic Index 
GROUPS 0day 5
th
 day 10
th
 day 15
th
 day 21
st
 day 
CTG -0.01±0.021 0.01±0.016 0.28±0.010 0.31±0.017 0.25±0.011 
HTG -0.003±0.019 0.190±0.014 0.48±0.015 0.691±0.009 0.98±0.015 
RTG -0.019±0.014 0.084±0.013 0.34±0.010 0.488±0.007 0.54±0.009 
TTG -0.001±0.005 -0.001±0.012 0.22±0.007 0.357±0.023 0.36±0.009 
**Mean ±SD (n=6) 
Inference 
The AI increased in TTG (0.36±0.009mg/dl), When compared with CTG 
(0.25±0.011mg/dl) p<0.01. The AI decreased in TTG (0.36±0.009mg/dl) when compared 
with HTG and RTG (0.98±0.015mg/dl, 0.54±0.009mg/dl respectively) p<0.01 shown in 
Table.30. 
 
Thus, Simvastatin-loaded chitosan nanoparticles showed a significantly better in- vivo 
performance than Simvastatin in reducing total CH and TG levels which is primarily 
attributed to the improved solubility and dissolution of nanoparticles. The present results 
suggest that HMG-CoA reductase inhibitors prevent the progression of hypercholesterolemia 
during treatment, though the plasma lipid levels remain much higher than in normal lipidemic 
rats. This may be due to the decreased HMG-CoA reductase activity and LDL receptor 
function in chronically fed cholesterol rats. The decrease in plasma lipid levels was more in 
TTG than in RTG. This may be due to the ability of Simvastatin to increase lipoprotein lipase 
activity in animals. 
 	
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11. SUMMARY AND CONCLUSION 
The present work involves the formulation development, optimization, in-vitro and in-vivo 
evaluation of Simvastatin loaded Chitosan nanoparticles for sustained release. 
 The Simvastatin, Chitosan were found to be compatible in FTIR study and DSC 
studies. 
 
 The Simvastatin Nanoparticles were prepared by Nanoprecipitation method. 
 
 Various concentration of chitosan were used to prepare Simvastatin nanoparticles and 
the maximum drug loading was found in F3. 
 
 SEM study showed that prepared nanoparticles were spherical in shape with a smooth 
surface. Particle size of prepared nanoparticles was found to be in the range between 
360nm and 480nm. 
 
 In-vitro drug release of the optimized formulation shows 95.66% release at the end of 
12 hours. 
 
 The release kinetics of the optimized Nanoparticles showed that it follows zero order 
release kinetics. The release of the drug from Nanoparticles was found to be by 
diffusion and Non-fickian release. 
 
 Stability studies of optimized nanoparticles were carried out according to ICH 
guidelines. It indicated that the Nanoparticles are stable and does not show any 
significant changes physical characteristics, drug content and dissolution. 
 
 The comparative in vivo hypolipidemic activity performed on albino rats, after 21days 
of treatment, showed that plasma CH and TG levels were significantly lower 
(98.34±0.596 mg/dl, 84.56±0.55 mg/dl respectively) (p < 0.01). 
 
  HDL-CH levels were significantly higher (36.29±0.602 mg/dl, p <0.01) in TTG 
compared to RTG.  
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 TTG showed a significantly better in vivo performance than RTG in terms of plasma 
lipid profile. The maximum percentage reduction of lipid levels were observed with 
Simvastatin nanoparticles. 
 
From the overall results, it is clear that the formulation F3 containing 1:3 drug: polymer 
ratio is the optimal formulation, as it produces sustained drug release. 
 
 
FUTURE SCOPE 
 
 Scale up studies of the optimized formulation. 
 
 In vivo – In vitro correlation studies. 
 
 Pharmacokinetic and toxicity study. 
 
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